0000912061-16-000043.txt : 20161025 0000912061-16-000043.hdr.sgml : 20161025 20161025090626 ACCESSION NUMBER: 0000912061-16-000043 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 46 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161025 DATE AS OF CHANGE: 20161025 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NATURAL HEALTH TRENDS CORP CENTRAL INDEX KEY: 0000912061 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190] IRS NUMBER: 592705336 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36849 FILM NUMBER: 161949396 BUSINESS ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 BUSINESS PHONE: 310-541-0888 MAIL ADDRESS: STREET 1: 609 DEEP VALLEY DRIVE STREET 2: SUITE 395 (EAST BUILDING) CITY: ROLLING HILLS ESTATES STATE: CA ZIP: 90274 10-Q 1 nhtc20161025_10q.htm 10-Q Document
false--12-31Q320160000912061YesAccelerated Filer0.0010.00150000000500000001297941412979414000020.0010.001500000050000000000P3Y8402021692218 0000912061 2016-01-01 2016-09-30 0000912061 2016-10-21 0000912061 2016-09-30 0000912061 2015-12-31 0000912061 2016-07-01 2016-09-30 0000912061 2015-01-01 2015-09-30 0000912061 2015-07-01 2015-09-30 0000912061 2014-12-31 0000912061 2015-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2016-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000912061 us-gaap:CashEquivalentsMember 2016-09-30 0000912061 us-gaap:CashEquivalentsMember 2015-12-31 0000912061 us-gaap:CashMember 2015-12-31 0000912061 us-gaap:CashMember 2016-09-30 0000912061 nhtc:BankDepositInAnticipationOfSubmittingDirectSellingLicenseApplicationMember 2015-09-30 0000912061 2016-01-01 2016-03-31 0000912061 nhtc:BankDepositInAnticipationOfSubmittingDirectSellingLicenseApplicationMember 2016-09-30 0000912061 2015-04-30 0000912061 country:CN 2016-09-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2016-09-30 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2015-12-31 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2016-09-30 0000912061 nhtc:MunicipalBondsAndNotesMember 2016-09-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-01-01 2016-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2016-09-30 0000912061 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember 2016-04-08 2016-04-08 0000912061 2016-08-26 2016-08-26 0000912061 2016-03-24 2016-03-24 0000912061 2016-05-20 2016-05-20 0000912061 2016-01-12 0000912061 2015-07-28 0000912061 2015-01-01 2015-12-31 0000912061 us-gaap:OtherNoncurrentAssetsMember nhtc:KoreanBusinessSegmentMember 2016-09-30 0000912061 nhtc:SecuritiesClassActionMember 2016-01-01 2016-01-31 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-09-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2013-02-01 2013-02-28 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-07-01 2016-09-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-09-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-04-29 2015-04-29 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-07-01 2016-09-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2015-07-01 2015-09-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-09-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-09-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-07-01 2015-09-30 0000912061 us-gaap:SubsequentEventMember 2016-10-23 2016-10-23 xbrli:pure nhtc:complaint xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:CNY iso4217:KRW


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q 
(Mark One)
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended September 30, 2016
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from ______ to _______
 
Commission File Number: 001-36849
NATURAL HEALTH TRENDS CORP.
(Exact name of registrant as specified in its charter)
Delaware
59-2705336
(State or other jurisdiction of
(I.R.S. Employer
incorporation or organization)
Identification No.)
609 Deep Valley Drive
Suite 395
Rolling Hills Estates, California 90274
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (310) 541-0888

 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for shorter period that the registrant was required to submit and post such files). Yes þ No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): 
Large accelerated filer o
Accelerated filer þ
Non-accelerated filer   o
Smaller reporting company o
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No þ
 
At October 21, 2016, the number of shares outstanding of the registrant’s common stock was 11,287,196 shares.




NATURAL HEALTH TRENDS CORP.
Quarterly Report on Form 10-Q
September 30, 2016
 
INDEX 
 




FORWARD-LOOKING STATEMENTS
 
This Quarterly Report on Form 10-Q, in particular “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation,” includes “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). When used in this report, the words or phrases “will likely result,” “expect,” “intend,” “will continue,” “anticipate,” “estimate,” “project,” “believe” and similar expressions are intended to identify “forward-looking statements” within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.
 
Forward-looking statements in this report speak only as of the date hereof, and forward looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.
 
For a summary of certain risks related to our business, see “Item 1A. Risk Factors” in our most recent Annual Report on Form 10-K, which includes the following:
We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants;
Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business;
Our operations in China are subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company;
Our failure to maintain and expand our member relationships could adversely affect our business;
The high level of competition in our industry could adversely affect our business;
Challenges by third parties to the legality of our business operations could harm our business;
We are currently being sued in three lawsuits alleging, among other things, that we made materially false and misleading statements regarding the legality of our business operations in China;
An increase in the amount of compensation paid to members would reduce profitability;
Failure of new products to gain member and market acceptance could harm our business;
Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business;
Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets;
New regulations governing the marketing and sale of nutritional supplements could harm our business;
Regulations governing the production and marketing of our personal care products could harm our business;
If we are found not to be in compliance with good manufacturing practices our operations could be harmed;
Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business;
Although our members are independent contractors, improper member actions that violate laws or regulations could harm our business;
Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results;
We have a limited product line;
We rely on a limited number of independent third parties to manufacture and supply our products;




Growth may be impeded by the political and economic risks of entering and operating foreign markets;
Currency exchange rate fluctuations could lower our revenue and net income;
Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income;
Transfer pricing regulations affect our business and results of operations;
We may be held responsible for certain taxes or assessments relating to the activities of our members, which could harm our financial condition and operating results;
We are currently involved in, and may in the future face, litigation that could harm our business;
We may be unable to protect or use our intellectual property rights;
We do not have a comprehensive product liability insurance program and product liability claims could hurt our business;
Our internal controls and accounting methods may require modification;
If we fail to achieve and maintain an effective system of internal controls in the future, we may not be able to accurately report our financial results or prevent fraud.  As a result, investors may lose confidence in our financial reporting;
We rely on and are subject to risks associated with our reliance upon information technology systems;
System failures and attacks could harm our business;
Terrorist attacks, cyber-attacks, acts of war, epidemics or other communicable diseases or any other natural disasters may seriously harm our business;
Because our systems, software and data reside on third-party servers, our access could be temporarily or permanently interrupted;
We may experience substantial negative cash flows, which may have a significant adverse effect on our business and could threaten our solvency;
If we experience negative cash flows, we may need to seek additional debt or equity financing, which may not be available on acceptable terms or at all.  If available, it could have a highly dilutive effect on the holdings of existing stockholders;
Disappointing quarterly revenue or operating results could cause the price of our common stock to fall;
Our common stock is particularly subject to volatility because of the industry in which we operate;
Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive; and
Future sales by us or our existing stockholders could depress the market price of our common stock.

Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our financial statements and the related notes.




PART I - FINANCIAL INFORMATION
 
Item 1. FINANCIAL STATEMENTS
  
NATURAL HEALTH TRENDS CORP.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
 
 
September 30, 2016
 
December 31, 2015
 
(Unaudited)
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
114,500

 
$
104,914

Accounts receivable
98

 
57

Inventories, net
14,842

 
10,455

Other current assets
3,540

 
2,286

Total current assets
132,980

 
117,712

Property and equipment, net
1,297

 
894

Goodwill
1,764

 
1,764

Restricted cash
3,090

 
3,166

Other assets
723

 
616

Total assets
$
139,854

 
$
124,152

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
3,114

 
$
2,862

Income taxes payable
655

 
379

Accrued commissions
18,620

 
19,634

Other accrued expenses
18,443

 
16,703

Deferred revenue
4,236

 
4,011

Deferred tax liability
60

 
60

Amounts held in eWallets
19,510

 
16,414

Other current liabilities
1,543

 
1,510

Total current liabilities
66,181

 
61,573

Long-term incentive
4,945

 
5,770

Total liabilities
71,126

 
67,343

Commitments and contingencies

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding

 

Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2016 and December 31, 2015
13

 
13

Additional paid-in capital
86,564

 
85,963

Retained earnings (accumulated deficit)
24,342

 
(9,647
)
Accumulated other comprehensive loss
(302
)
 
(101
)
Treasury stock, at cost; 1,692,218 and 840,202 shares at September 30, 2016 and December 31, 2015, respectively
(41,889
)
 
(19,419
)
Total stockholders’ equity
68,728

 
56,809

Total liabilities and stockholders’ equity
$
139,854

 
$
124,152

 
See accompanying notes to consolidated financial statements.

1



NATURAL HEALTH TRENDS CORP. 
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(In thousands, except per share data)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net sales
$
70,679

 
$
80,779

 
$
225,416

 
$
191,204

Cost of sales
13,627

 
16,001

 
42,966

 
39,025

Gross profit
57,052

 
64,778

 
182,450

 
152,179

Operating expenses:
 
 
 
 
 
 
 
Commissions expense
30,578

 
40,036

 
103,547

 
93,443

Selling, general and administrative expenses
 
(including stock-based compensation expense of $10 and $21 during the three months ended September 30, 2016 and 2015, respectively, and $94 and $56 during the nine months ended September 30, 2016 and 2015, respectively)
11,170

 
9,867

 
34,505

 
24,571

Depreciation and amortization
96

 
72

 
276

 
181

Total operating expenses
41,844

 
49,975

 
138,328

 
118,195

Income from operations
15,208

 
14,803

 
44,122

 
33,984

Other income (expense), net
48

 
(135
)
 
40

 
(112
)
Income before income taxes
15,256

 
14,668

 
44,162

 
33,872

Income tax provision
2,699

 
137

 
8,124

 
330

Net income
$
12,557

 
$
14,531

 
$
36,038

 
$
33,542

Income per common share:
 
 
 
 
 
 
 
Basic
$
1.12

 
$
1.19

 
$
3.15

 
$
2.71

Diluted
$
1.12

 
$
1.18

 
$
3.14

 
$
2.70

Weighted-average number of common shares outstanding:
 
 
 
 
 
 
 
Basic
11,209

 
12,239

 
11,437

 
12,364

Diluted
11,232

 
12,284

 
11,463

 
12,439

Cash dividends declared per common share
$
0.07

 
$
0.04

 
$
0.18

 
$
0.09

 
See accompanying notes to consolidated financial statements.
 

2



NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)
(In thousands)
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net income
$
12,557

 
$
14,531

 
$
36,038

 
$
33,542

Other comprehensive loss, net of tax:
 
 
 
 
 
 
 
Foreign currency translation adjustment
(54
)
 
(118
)
 
(329
)
 
35

Release of cumulative translation adjustment

 

 
132

 
(82
)
Net change in foreign currency translation adjustment
(54
)
 
(118
)
 
(197
)
 
(47
)
Unrealized (losses) gains on available-for-sale securities
(11
)
 

 
(4
)
 
2

Comprehensive income
$
12,492

 
$
14,413

 
$
35,837

 
$
33,497

 
See accompanying notes to consolidated financial statements.
 

3



NATURAL HEALTH TRENDS CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(In thousands)
 
 
Nine Months Ended September 30,
 
2016
 
2015
CASH FLOWS FROM OPERATING ACTIVITIES:
 
 
 
Net income
$
36,038

 
$
33,542

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
276

 
181

Stock-based compensation
94

 
56

Cumulative translation adjustment realized in net income
132

 
(82
)
Changes in assets and liabilities:
 
 
 
Accounts receivable
(36
)
 
(217
)
Inventories, net
(4,382
)
 
(2,904
)
Other current assets
(1,208
)
 
(736
)
Other assets
(91
)
 
(264
)
Accounts payable
252

 
2,140

Income taxes payable
278

 
190

Accrued commissions
(1,045
)
 
11,832

Other accrued expenses
3,459

 
8,397

Deferred revenue
222

 
1,844

Amounts held in eWallets
3,098

 
11,354

Other current liabilities
26

 
93

Long-term incentive
(825
)
 
(229
)
Net cash provided by operating activities
36,288

 
65,197

CASH FLOWS FROM INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment, net
(679
)
 
(645
)
Increase in restricted cash

 
(3,028
)
Net cash used in investing activities
(679
)
 
(3,673
)
CASH FLOWS FROM FINANCING ACTIVITIES:
 
 
 
Proceeds from exercise of warrants

 
309

Repurchase of common stock
(23,704
)
 
(11,079
)
Dividends paid
(2,049
)
 
(1,111
)
Net cash used in financing activities
(25,753
)
 
(11,881
)
Effect of exchange rates on cash and cash equivalents
(270
)
 
106

Net increase in cash and cash equivalents
9,586

 
49,749

CASH AND CASH EQUIVALENTS, beginning of period
104,914

 
44,816

CASH AND CASH EQUIVALENTS, end of period
$
114,500

 
$
94,565

SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:
 
 
 
Cash paid for income taxes, net of refunds
$
7,994

 
$
152

Issuance of treasury stock
$
1,741

 
$
666

 
See accompanying notes to consolidated financial statements.

4



NATURAL HEALTH TRENDS CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Nature of Operations 
 
Natural Health Trends Corp. (the “Company”), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. In most markets, the Company sells its products to a network of members referred to the Company by other members.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: North America; Greater China, which consists of Hong Kong, Taiwan and China; South Korea; Singapore; Japan; and Europe. The Company also operates within certain Commonwealth of Independent States (Russia and Kazakhstan) through an engagement with a local service provider.

Basis of Presentation 
 
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2015 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 4, 2016.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
 
Use of Estimates 
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.
 
The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with obsolete inventory, the fair value of goodwill, revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

Cash and Cash Equivalents
 
As of September 30, 2016, cash and cash equivalents include $5.8 million held in banks located within China subject to foreign currency controls.
 

5



Additionally, as of September 30, 2016, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2016 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.
 
Cash and cash equivalents at the end of each period were as follows (in thousands):
 
September 30, 2016
 
December 31, 2015
Cash
$
57,130

 
$
47,431

Cash equivalents
57,370

 
57,483

Total cash and cash equivalents
$
114,500

 
$
104,914



Restricted Cash
 
In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million (USD 3.0 million at September 30, 2016) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.

Other Accrued Expenses
 
Other accrued expenses at the end of each period were as follows (in thousands):
 
September 30, 2016
 
December 31, 2015
Sales returns
$
1,215

 
$
1,552

Employee-related
14,140

 
11,064

Warehousing, inventory-related and other
3,088

 
4,087

Total other accrued expenses
$
18,443

 
$
16,703



Income Taxes
 
The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the nine months ended September 30, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate.


6



The Company and its subsidiaries file income tax returns in the United States, various states, and foreign jurisdictions. The Company is no longer subject to U.S. federal income tax examinations for years prior to 2012, and is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.
 
Fair Value of Financial Instruments
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
September 30, 2016
 
December 31, 2015
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains (Losses)
 
Fair Value
Municipal bonds and notes
$
36,785

 
$
(3
)
 
$
36,782

 
$
35,222

 
$
2

 
$
35,224

Corporate debt securities
7,035

 
(3
)
 
7,032

 
5,029

 
(5
)
 
5,024

Financial institution instruments
13,556

 

 
13,556

 
17,235

 

 
17,235

Total available-for-sale investments
$
57,376

 
$
(6
)
 
$
57,370

 
$
57,486

 
$
(3
)
 
$
57,483


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.
 
Accumulated Other Comprehensive Loss
 
The changes in accumulated other comprehensive loss by component for the first nine months of 2016 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2015
$
(99
)
 
$
(2
)
 
$
(101
)
Other comprehensive loss
(329
)
 
(4
)
 
(333
)
Amounts reclassified out of accumulated other comprehensive loss
132

 

 
132

Balance, September 30, 2016
$
(296
)
 
$
(6
)
 
$
(302
)

 
Revenue Recognition
 
Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.
 

7



Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.
 
Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales.  Event and training revenue is deferred and recognized as the event or training occurs.
 
Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
 
Income Per Share

Diluted income per share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

Warrants to purchase 88,087 shares of common stock were exercised in April 2015.
 
The following tables illustrates the computation of basic and diluted income per share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended September 30,
 
2016
 
2015
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
12,557

 
11,209

 
$
1.12

 
$
14,531

 
12,239

 
$
1.19

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
23

 
 

 

 
45

 
 

Diluted EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
12,557

 
11,232

 
$
1.12

 
$
14,531

 
12,284

 
$
1.18

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30,
 
2016
 
2015
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
36,038

 
11,437

 
$
3.15

 
$
33,542

 
12,364

 
$
2.71

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Warrants to purchase common stock

 

 
 

 

 
27

 
 

Non-vested restricted stock

 
26

 
 

 

 
48

 
 

Diluted EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
36,038

 
11,463

 
$
3.14

 
$
33,542

 
12,439

 
$
2.70



8




For the nine months ended September 30, 2016, 42,506 shares of non-vested restricted stock were not included in the computation of diluted income per share as their effect would have been anti-dilutive.

Recently Issued and Adopted Accounting Pronouncements
 
In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 
Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

3. STOCK-BASED COMPENSATION
 
Stock-based compensation expense totaled $10,000 and $21,000 for the three months ended September 30, 2016 and 2015, respectively, and $94,000 and $56,000 for the nine months ended September 30, 2016 and 2015, respectively. No tax benefits were attributed to the stock-based compensation because a valuation allowance was maintained for substantially all net deferred tax assets. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional $64,000 in stock-based compensation expense for the three months ended March 31, 2016.


9



At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted.

On April 8, 2016, the Company initially granted 51,015 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2015 performance incentives. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015

 
$

Granted
51,015

 
34.13

Vested
(8,509
)
 
34.13

Nonvested at September 30, 2016
42,506

 
34.13



The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015
44,712

 
$
12.15

Granted

 

Vested
(16,773
)
 
12.15

Nonvested at September 30, 2016
27,939

 
12.15


 
As of September 30, 2016, total unrecognized stock-based compensation expense related to non-vested restricted stock was $49,000, which is expected to be recognized over a weighted-average period of 1.3 years.

4. STOCKHOLDERS’ EQUITY
 
Dividends
 
The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2016 (in thousands, except per share data):

Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
July 19, 2016
 
$
0.07

 
$
787

 
August 16, 2016
 
August 26, 2016
April 21, 2016
 
$
0.06

 
$
686

 
May 10, 2016
 
May 20, 2016
March 1, 2016
 
$
0.05

 
$
576

 
March 16, 2016
 
March 24, 2016
 
 
$
0.18

 
$
2,049

 
 
 
 



10



Treasury Stock

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

During February 2016, pursuant to the stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. During the nine months ended September 30, 2016, the Company purchased a total of 903,031 shares of its common stock for an aggregate purchase price of $23.7 million, plus transaction costs. Pursuant to the Company’s stock repurchase program first approved on July 28, 2015, the Company purchased a total of 268,706 shares of its common stock for an aggregate purchase price of $10.0 million during the year ended December 31, 2015. As of September 30, 2016, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.

5. COMMITMENTS AND CONTINGENCIES

Consumer Indemnity

As required by the Door-to-Door Sales Act in South Korea, the Company maintains insurance for consumer indemnity claims with a mutual aid cooperative by possessing a mutual aid contract with Mutual Aid Cooperative & Consumer (the “Cooperative”). The contract secures payment to members in the event that the Company is unable to provide refunds to members. Typically, requests for refunds are paid directly by the Company according to the Company’s normal Korean refund policy, which requires that refund requests be submitted within three months. Accordingly, the Company estimates and accrues a reserve for product returns based on this policy and its historical experience. Depending on the sales volume, the Company may be required to increase or decrease the amount of the contract. The maximum potential amount of future payments the Company could be required to make to address actual member claims under the contract is equivalent to three months of rolling sales. At September 30, 2016, non-current other assets include KRW 223 million (USD $203,000) underlying the contract, which can be utilized by the Cooperative to fund any outstanding member claims. The Company believes that the likelihood of utilizing these funds to provide for members claims is remote.

Securities Class Action

In January 2016, two purported securities class action complaints were filed against the Company and its top executives. On March 29, 2016, the court consolidated the purported securities class actions, appointed two Lead Plaintiffs, Messrs. Dao and Juan, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class in the consolidated action. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of certain of our stockholders under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., Chris T. Sharng, and Timothy S. Davidson, and to assert claims under Section 20(a) of the Securities Exchange Act of 1934 against Chris T. Sharng, Timothy S. Davidson, and George K. Broady. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company filed a motion to dismiss the consolidated complaint on June 15, 2016 and a reply in support of its motion to dismiss on August 22, 2016. The Court has not ruled on the Company’s motion to dismiss yet. The Company believes that these claims are without merit and intends to vigorously defend against the allegations in the consolidated complaint.


11



Shareholder Derivative Claim

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. The derivative cases have been stayed pending the resolution of the motion to dismiss in the securities class action, and the defendants have not yet filed a response. Nevertheless, the defendants believe that these claims are without merit and intend to vigorously defend against the allegations in these derivative actions.

The consolidated class action and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.

Other Claims

The Company is currently in the early stages of a legal matter that involves one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.

6. RELATED PARTY TRANSACTIONS

Product Royalties

On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called Soothe™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Royalties recognized for the three months ended September 30, 2016 and 2015 were $700 and $1,300, respectively, and $2,700 and $5,200 for the nine months ended September 30, 2016 and 2015, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice. Otherwise, the agreement terminates March 31, 2020.

In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called ReStor™.  Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were $106,000 and $154,000 for the three months ended September 30, 2016 and 2015, respectively, and $386,000 and $410,000 for the nine months ended September 30, 2016 and 2015, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.

7. SUBSEQUENT EVENT
 
On October 23, 2016, the Board of Directors declared a quarterly cash dividend of $0.08 and a special cash dividend of $0.35 on each share of common stock outstanding. Such dividends are payable on November 25, 2016 to stockholders of record on November 15, 2016. Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.


12



Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Business Overview
 
We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: North America; Greater China, which consists of Hong Kong, Taiwan and China; Commonwealth of Independent States (“CIS”), which consists of Russia and Kazakhstan; South Korea; Japan; Singapore; and Europe. In most markets, we sell our products to a network of members referred to us by other members.
 
Our member network operates in a seamless manner from market to market, except for the Chinese market, where we sell to consumers through an e-commerce platform, and the CIS market, where we operate through our engagement of a third-party service provider. Our engagement of a third-party service provider in the CIS market results in a different economic structure than our other markets. Otherwise, we believe that all of our other operating segments are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. There is no separate segment manager who is held accountable by our chief operating decision-makers, or anyone else, for operations, operating results and planning for neither the Chinese market or CIS market on a stand-alone basis, and neither market is material for the periods presented. As such, we consider ourselves to be in a single reporting segment and operating unit structure. 
 
As of September 30, 2016, we were conducting business through 122,900 active members, compared to 126,440 three months ago and 94,700 a year ago. We consider a member “active” if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia. We also plan to invest resources in Central and South America.
 
We generate approximately 98% of our net sales from subsidiaries located outside North America, with sales of our Hong Kong subsidiary representing 93% of net sales in the latest fiscal quarter. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and potential inability to obtain necessary product registrations. For further information regarding some of the risks associated with the conduct of our business in China, see generally in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015, and more specifically under the captions “Risk Factors - Because our Hong Kong operations account for a substantial portion of our overall business...” and “Risk Factors - Our operations in China are subject to compliance with a myriad of applicable laws and regulations...”.
 
China has been and continues to be our most important business development project. We operate an e-commerce direct selling model in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China. We believe that neither of these activities requires a direct selling license in China, which we do not currently hold. We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China. If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business. Increased sales in China that could be derived from obtaining a direct selling license may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements. We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.


13



Income Statement Presentation
 
We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published prices. Product sales are recorded when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. We bill members for shipping charges and recognize the freight revenue in net sales. Event and training revenue is deferred and recognized as the event or training occurs.
 
Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.
 
Member commissions are typically our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions, generally in the currency for the country they were registered, for product purchases by their down-line member network across all geographic markets, except China, where our subsidiary maintains an e-commerce retail platform and does not pay any commissions. This “seamless” compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:
through commissions paid on product purchases made by their down-line members; and
through retail markups on sales of products purchased by members at wholesale prices (in the majority of our markets, sales are for personal consumption only and income may not be earned through retail mark-ups on sales in that market).
 
Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product’s wholesale price. As the member’s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member’s commissionable group increases as the number of memberships directly below the member increases. Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Members can also earn income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for the first nine months of 2016 and 2015, represented 46% and 49% of net sales, respectively. From time to time we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions. From time to time we also enter into agreements for business or market development, which may result in additional compensation to specific members.
 
Selling, general and administrative expenses consist of administrative compensation and benefits (including stock-based compensation), travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses. In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly.

The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.  The resulting translation adjustments are recorded directly into accumulated other comprehensive income.
 

14



Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate.  Most of our product purchases from third-party manufacturers are transacted in U.S. dollars.  Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar.


Results of Operations 
 
The following table sets forth our operating results as a percentage of net sales for the periods indicated.
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
Net sales
100.0
%
 
100.0
 %
 
100.0
%
 
100.0
 %
Cost of sales
19.3

 
19.8

 
19.1

 
20.4

Gross profit
80.7

 
80.2

 
80.9

 
79.6

Operating expenses:
 
 
 
 
 
 
 
Commissions expense
43.3

 
49.6

 
45.9

 
48.9

Selling, general and administrative expenses
15.8

 
12.2

 
15.3

 
12.8

Depreciation and amortization
0.1

 
0.1

 
0.1

 
0.1

Total operating expenses
59.2

 
61.9

 
61.3

 
61.8

Income from operations
21.5

 
18.3

 
19.6

 
17.8

Other income (expense), net
0.1

 
(0.1
)
 

 
(0.1
)
Income before income taxes
21.6

 
18.2

 
19.6

 
17.7

Income tax provision
3.8

 
0.2

 
3.6

 
0.2

Net income
17.8
%
 
18.0
 %
 
16.0
%
 
17.5
 %
 
Net Sales
 
The following table sets forth revenue by market for the periods indicated (in thousands):
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2016
 
2015
 
2016
 
2015
North America
$
1,345

 
1.9
%
 
$
1,136

 
1.4
%
 
$
4,403

 
2.0
%
 
$
4,247

 
2.2
%
Hong Kong
65,904

 
93.3

 
75,900

 
94.0

 
207,410

 
92.0

 
178,017

 
93.2

China
1,354

 
1.9

 
1,544

 
1.9

 
7,169

 
3.2

 
2,855

 
1.5

Taiwan
1,329

 
1.9

 
1,685

 
2.1

 
4,453

 
2.0

 
4,049

 
2.1

South Korea
152

 
0.2

 
178

 
0.2

 
544

 
0.2

 
906

 
0.5

Japan
24

 

 
22

 

 
60

 

 
64

 

Singapore
57

 
0.1

 

 

 
99

 

 

 

Russia, Kazakhstan and Ukraine
203

 
0.3

 
225

 
0.3

 
630

 
0.3

 
806

 
0.4

Europe
311

 
0.4

 
89

 
0.1

 
648

 
0.3

 
260

 
0.1

Total
$
70,679

 
100.0
%
 
$
80,779

 
100.0
%
 
$
225,416

 
100.0
%
 
$
191,204

 
100.0
%
 
Net sales were $70.7 million for the three months ended September 30, 2016 compared with $80.8 million for the comparable period a year ago, a decrease of $10.1 million, or 13%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, decreased $10.0 million, or 13%, over the comparable period a year ago. The sales decrease was partly attributable to the special measures the Chinese government implemented in preparation of the G20 Summit in Hangzhou, one of our top markets, in which they relocated city residents, emptied entire districts, blocked urban traffic and shut down businesses in July, August and early September. In addition, the second and third quarter of 2015 included a supplemental incentive trip promotion to the U.S., which proved to be appealing to our members and contributed to increased sales. A similar supplemental incentive trip was not offered during 2016.

15



 
Net sales were $225.4 million for the nine months ended September 30, 2016 compared with $191.2 million for the comparable period a year ago, an increase of $34.2 million, or 18%.  Hong Kong net sales, substantially all of which were shipped to members residing in China, increased $29.4 million, or 17%, over the comparable period a year ago. Hong Kong experienced an increase of 27,000 active members, or 31%, from September 30, 2015 to September 30, 2016, which contributed to the increase in product sales volume. We also launched new Wellness products in the first nine months of 2016, which contributed approximately $5.8 million to our top-line growth. However, we believe our net sales increase was adversely impacted by the factors identified above that impacted our quarterly results, as well as the devaluation of the Chinese yuan, which has depreciated by 6% against the Hong Kong dollar and has indirectly affected our financial results by increasing the product pricing in the currency of our Chinese members.
 
Outside of our Hong Kong business, net sales increased $4.8 million, or 37%, over the comparable nine month period a year ago, driven by a 151% increase in our China e-commerce business, a 149% increase in Europe and a 10% increase in Taiwan, offset by the performance of South Korea, which decreased 40% and our CIS market, which decreased 22%. The $4.3 million net sales increase in our China e-commerce business was primarily driven by our Home product line.
 
As of September 30, 2016, deferred revenue was $4.2 million, which primarily consisted of $1.6 million pertaining to unshipped product orders, $2.2 million pertaining to auto ship advances and $423,000 pertaining to unamortized enrollment package revenue.
 
Gross Profit
 
Gross profit was 80.7% of net sales for the three months ended September 30, 2016 compared with 80.2% of net sales for the three months ended September 30, 2015. The gross profit margin percentage increase is due to higher event and training revenue.
 
Gross profit increased to 80.9% of net sales for the nine months ended September 30, 2016 compared with 79.6% of net sales for the nine months ended September 30, 2015 primarily due to higher event and training revenue, higher product margins and lower logistics costs.

Commissions
 
Commissions were 43.3% of net sales for the three months ended September 30, 2016, compared with 49.6% of net sales for the three months ended September 30, 2015, and 45.9% of net sales for the nine months ended September 30, 2016, compared with 48.9% for the comparable period a year ago. The decrease as a percentage of net sales for both the three and nine months periods ended September 30, 2016 primarily resulted from lower estimated costs for on-going cash and other incentive programs.
 
Selling, General and Administrative Expenses
 
Selling, general and administrative expenses were $11.2 million for the three months ended September 30, 2016 compared with $9.9 million in the same period a year ago. Selling, general and administrative expenses increased by 13% during the three month period mainly due to an increase in the cost of member training events, professional fees and event costs as compared to the same period in the prior year.

For the nine months ended September 30, 2016, selling, general and administrative expenses were $34.5 million compared with $24.6 million for the comparable period a year ago. Selling, general and administrative expenses increased by 40% during the nine month period mainly due to an increase in employee-related costs, the cost of member training events, professional fees, event costs, as well as an increase in credit card fees and assessments due to higher net sales as compared to the same period in the prior year.

 

16



Income Taxes
 
An income tax provision of $2.7 million and $137,000 was recognized during the three month periods ended September 30, 2016 and 2015, respectively. An income tax provision of $8.1 million and $330,000 was recognized during the nine month periods ended September 30, 2016 and 2015, respectively. As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. We repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the nine months ended September 30, 2016 was generated from current foreign earnings. We will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. corporate tax rate.

Liquidity and Capital Resources
 
At September 30, 2016, our cash and cash equivalents totaled $114.5 million. Total cash and cash equivalents increased by $9.6 million from December 31, 2015 to September 30, 2016. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2016, we had $57.4 million in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included $5.8 million held in banks located within China subject to foreign currency controls.

As of September 30, 2016, the ratio of current assets to current liabilities was 2.01 to 1.00 and we had $66.8 million of working capital. Working capital as of September 30, 2016 increased $10.7 million compared to our working capital as of December 31, 2015, due primarily to increases in cash from operations and inventory, offset by an increase to our eWallet liability during the nine months ended September 30, 2016.
 
Cash provided by operations for the first nine months of 2016 was $36.3 million compared with $65.2 million in the comparable period of 2015. The decrease in operating cash flows resulted primarily from the timing of increased commission-related payments, the impact of our members’ utilization of our eWallet functionality and U.S. income tax payments of $7.4 million, offset by our increased net income during the first nine months of 2016.
 
Cash flows used in investing activities totaled $679,000 during the first nine months of 2016. Software development costs of $518,000 were incurred during the first nine months of 2016 for our Oracle ERP upgrade and enhancement of our back office software platform. Cash flows used in investing activities totaled $3.7 million during the first nine months of 2015 and consisted primarily of our June 2015 funding of a bank deposit amount in the amount of CNY 20 million (USD $3.3 million) for our direct selling license application.  
 
Cash flows used in financing activities during the first nine months of 2016 totaled $25.8 million. We used $23.7 million to repurchase shares of our common stock. On January 12, 2016, the Board of Directors authorized an increase to our stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that our earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, we may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require us to acquire a specific number of shares, and may be suspended from time to time or discontinued. During February 2016, pursuant to the stock repurchase program, we authorized our broker to proceed with the purchase of shares of our common stock in the open market. During the first nine months of 2016, the stock repurchase program resulted in our purchasing a total of 903,031 shares of our common stock for an aggregate purchase price of $23.7 million, plus transaction costs. As of September 30, 2016, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax. Cash flows used in financing activities during the first nine months of 2015 totaled $11.9 million, and consisted primarily of $11.1 million in stock repurchases.

17




Other financing cash flows during the first nine months of 2016 included the following cash dividend payments (in thousands, except per share amounts):
Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
July 19, 2016
 
$
0.07

 
$
787

 
August 16, 2016
 
August 26, 2016
April 21, 2016
 
$
0.06

 
$
686

 
May 10, 2016
 
May 20, 2016
March 1, 2016
 
$
0.05

 
$
576

 
March 16, 2016
 
March 24, 2016
 
 
$
0.18

 
$
2,049

 
 
 
 

On October 23, 2016, the Board of Directors declared a cash dividend of $0.08 and a special cash dividend of $0.35 on each share of common stock outstanding. Such dividends are payable on November 25, 2016 to stockholders on record on November 15, 2016. Payment of any future dividends on shares of common stock will be at the discretion of our Board of Directors.

We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.
 
We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently we do not believe that will be necessary.

Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a China direct selling license application. We also plan to invest resources in Central and South America.
 
Critical Accounting Policies and Estimates 
 
A summary of our significant accounting policies is provided in Note 1 of the Notes to Consolidated Financial Statements in Item 1 of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 4, 2016. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
 
Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management’s most subjective judgments.  Management believes our critical accounting policies and estimates are those related to obsolete inventory and the fair value of goodwill, revenue recognition, as well as those used in the determination of liabilities related to sales returns, member commissions and income taxes.
 
Inventory Valuation. We review our inventory carrying value and compare it to the net realizable value of our inventory and any inventory value in excess of net realizable value is written down. In addition, we review our inventory for obsolescence and any inventory identified as obsolete is reserved or written off. Our determination of obsolescence is based on assumptions about the demand for our products, product expiration dates, estimated future sales, and management’s future plans. Also, if actual sales or management plans are less favorable than those originally projected by management, additional inventory reserves or write-downs may be required. At September 30, 2016 and December 31, 2015, our inventory value was $14.8 million and $10.5 million, respectively, net of reserves of $21,000 and $29,000 at September 30, 2016 and December 31, 2015, respectively. No significant provision was recorded during the periods presented.
 

18



Valuation of Goodwill.  We assess qualitative factors in order to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, through this qualitative assessment, the conclusion is made that it is more likely than not that a reporting unit’s fair value is less than its carrying amount, a two-step impairment test is performed. Our policy is to test for impairment annually during the fourth quarter. At September 30, 2016 and December 31, 2015, goodwill of $1.8 million was reflected on our balance sheet. No impairment of goodwill was recognized during the periods presented.
 
Allowance for Sales Returns. An allowance for sales returns is provided during the period the product is shipped.  The allowance is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.  Sales returns were 2% and 1% of sales for the nine-month periods ended September 30, 2016 and 2015, respectively.  The allowance for sales returns was $1.2 million and $1.6 million at September 30, 2016 and December 31, 2015, respectively.  No material changes in estimates have been recognized during the periods presented.

Revenue Recognition.  Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product are recorded as deferred revenue. Such amounts totaled $1.6 million and $1.8 million at September 30, 2016 and December 31, 2015, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.
 
Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal. At September 30, 2016 and December 31, 2015, enrollment package revenue totaling $423,000 and $331,000 was deferred, respectively. Although we have no immediate plans to significantly change the terms or conditions of enrollment packages, any changes in the future could result in additional revenue deferrals or could cause us to recognize the deferred revenue over a longer period of time. Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member’s cumulative commission income reaches a certain threshold, a percentage of the member’s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.  Such advances were $2.2 million and $1.6 million at September 30, 2016 and December 31, 2015, respectively.
 
Member Commissions. Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.  Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product’s wholesale price.  We accrue member commissions when earned and pay commissions on product sales generally two weeks following the end of the weekly sales period.
 
In some markets, we also pay certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on member commissions earned by up to three generations of personally enrolled members. Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.  These incentives may be both monetary and non-monetary in nature.  We estimate and accrue the costs associated with incentives over the duration of the qualification period based on member achievement of the qualification requirements. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled $18.6 million and $19.6 million at September 30, 2016 and December 31, 2015, respectively.
 
Income Taxes.  We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. During the third quarter of 2015, the valuation allowance against U.S. net operating losses was removed, and a corresponding deferred tax liability was recognized as we determined that a portion of our undistributed foreign earnings were no longer deemed reinvested indefinitely. During the first quarter of 2016, these net operating losses were fully utilized to offset the repatriation of foreign earnings. As of September 30, 2016, a valuation allowance remained against the existing U.S. deferred tax assets and certain deferred tax assets of non-U.S. subsidiaries. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized.
 

19



Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. An income tax provision of $2.7 million and $137,000 was recognized during the three-month periods ended September 30, 2016 and 2015, respectively, and $8.1 million and $330,000 was recognized during the nine-month periods ended September 30, 2016 and 2015, respectively. As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. We will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. corporate tax rate.

We believe that we operate in compliance with all applicable transfer pricing laws and we intend to continue to operate in compliance with such laws. However, there can be no assurance that we will continue to be found to be operating in compliance with transfer pricing laws, or that those laws would not be modified, which, as a result, may require changes in our operating procedures. If the United States Internal Revenue Service or the taxing authorities of any other jurisdiction were to successfully challenge these agreements, plans, or arrangements, or require changes in our transfer pricing practices, we could be required to pay higher taxes, interest and penalties, and our earnings would be adversely affected.
 
Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
We have operations both internationally and within the United States, and we are exposed to market risks in the ordinary course of our business. These risks include primarily interest rate, foreign exchange and inflation risks.

Interest Rate Fluctuation Risk

Our cash and cash equivalents consist of cash, available-for-sale securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The primary objective of our investment in available-for-sale securities is to preserve principal while maximizing income without significantly increasing risk. Because our cash and cash equivalents have a relatively short maturity, our portfolio's fair value is relatively insensitive to interest rate changes. In future periods, we will continue to evaluate our investment policy relative to our overall objectives.

Foreign Currency Exchange Risk

We have foreign currency risks related to our revenue and expenses denominated in currencies other than the U.S. dollar. Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar. Our foreign currency exchange rate exposure to South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Canadian dollar, and European euro represented approximately 7% and 6% of our revenue during the nine months ended September 30, 2016 and 2015, respectively. We have experienced and will continue to experience fluctuations in our net income as a result of transaction gains and losses related to translating certain balances denominated in currencies other than the U.S. dollar.

Our foreign currency exchange rate exposure may increase in the near future as we develop opportunities in Southeast Asia, Canada, Central America, South America and Europe. Additionally, our foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar. We also experience indirect exchange rate exposure due to the recent devaluation of the Chinese yuan, which has depreciated 6% against the Hong Kong dollar and has eroded our Chinese members purchasing power. Given our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition. Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.

Inflation Risk

We do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we might not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition and results of operations.


20



Item 4. CONTROLS AND PROCEDURES
 
Disclosure Controls and Procedures
 
Management, with the participation of the Company’s principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of September 30, 2016. The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including the Company’s principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, the principal executive officer and principal financial officer concluded that, as of September 30, 2016, the Company’s disclosure controls and procedures were effective.
 
Changes in Internal Control over Financial Reporting
 
There were no changes in internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2016 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

21



PART II — OTHER INFORMATION
 
Item 1. LEGAL PROCEEDINGS

Securities Class Action
 
In January 2016, two purported securities class action complaints were filed against us and our top executives in the United States District Court for the Central District of California: Ford v. Natural Health Trends Corp. and Li v. Natural Health Trends Corp. On March 29, 2016, the court consolidated the purported class actions, appointed two Lead Plaintiffs, Messrs. Dao and Juan, in the consolidated action and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class in the consolidated action. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of certain of our stockholders under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., Chris T. Sharng, and Timothy S. Davidson, and to assert claims under Section 20(a) of the Securities Exchange Act of 1934 against Chris T. Sharng, Timothy S. Davidson, and George K. Broady. The consolidated complaint alleges, inter alia, that we made materially false and misleading statements regarding the legality of our business operations in China, including running an allegedly illegal multi-level marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. We filed a motion to dismiss the consolidated complaint on June 15, 2016 and a reply in support of our motion to dismiss on August 22 2016. The Court has not ruled on our motion to dismiss yet. We believe that these claims are without merit and intend to vigorously defend against the allegations in the consolidated complaint.

Shareholder Derivative Claim

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of our officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed us and our assets. The Derivative Complaints allege, inter alia, that we made materially false and misleading statements regarding the legality of our business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. The derivative cases have been stayed pending the resolution of the motion to dismiss in the securities class action, and the defendants have not yet filed a response. Nevertheless, the defendants believe that these claims are without merit and intend to vigorously defend against the allegations in the derivative actions.

Item 1A. RISK FACTORS
 
Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2015, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2015.
 
Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES
 
None.
 
Item 4. MINE SAFETY DISCLOSURES
 
Not applicable.
 

22



Item 5. OTHER INFORMATION
 
None.
 
Item 6. EXHIBITS
 
Exhibit
Number
 
 
Exhibit Description
 
 
 
31.1
 
Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
 
Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
 
Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
 
XBRL Instance
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation

23



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
NATURAL HEALTH TRENDS CORP.
 
 
 
 
Date: October 25, 2016
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 

24



EXHIBIT INDEX
 
Exhibit
Number
 
Exhibit Description
 
 
 
31.1
 
Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2
 
Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1
 
Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
 
XBRL Instance
101.SCH
 
XBRL Taxonomy Extension Schema
101.CAL
 
XBRL Taxonomy Extension Calculation
101.DEF
 
XBRL Taxonomy Extension Definition
101.LAB
 
XBRL Taxonomy Extension Labels
101.PRE
 
XBRL Taxonomy Extension Presentation

25
EX-31.1 2 ex31-1.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
 
CERTIFICATION
 
I, Chris T. Sharng, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: October 25, 2016
/s/ Chris T. Sharng
 
 
Chris T. Sharng
 
 
President
 
 
(Principal Executive Officer)
 


EX-31.2 3 ex31-2.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
 
CERTIFICATION
 
I, Timothy S. Davidson, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;
 
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.  The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
5.  The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date: October 25, 2016
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 


EX-32.1 4 ex32-1.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1
 

CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Natural Health Trends Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2016, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
 
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: October 25, 2016
/s/ Chris T. Sharng
 
 
Chris T. Sharng
 
 
President
 
 
(Principal Executive Officer)
 
 
 
 
 
 
 
Date: October 25, 2016
/s/ Timothy S. Davidson
 
 
Timothy S. Davidson
 
 
Senior Vice President and Chief Financial Officer
 
 
(Principal Financial Officer)
 
 
The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-101.SCH 5 nhtc-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2110100 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - RELATED PARTY TRANSACTIONS - NARRATIVE (Detail) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - STOCK-BASED COMPMENSATION link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - STOCK-BASED COMPMENSATION - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - STOCK-BASED COMPMENSATION - RESTRICTED STOCK ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - STOCK-BASED COMPMENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - STOCKHOLDERS' EQUITY - NARRATIVE (Detail) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - AVAILABLE-FOR-SALE INVESTMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2407408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - BASIC AND DILUTED EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CASH AND CASH EQUIVALENTS (Details) link:presentationLink link:calculationLink link:definitionLink 2407407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CHANGES IN ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NARRATIVE (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - OTHER ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 2207201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2307302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 nhtc-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 nhtc-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 nhtc-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Accounting Policies [Abstract] Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Cash Cash [Member] Cash Equivalents Cash Equivalents [Member] Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Document Period End Date Document Period End Date Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Summary of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Income Statement [Abstract] Stock-based compensation expense included in selling, general, and administrative expense Allocated Share-based Compensation Expense Net sales Sales Revenue, Goods, Net Cost of sales Cost of Goods Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Commissions expense Sales Commissions and Fees Selling, general and administrative expenses (including stock-based compensation expense of $10 and $21 during the three months ended September 30, 2016 and 2015, respectively, and $94 and $56 during the nine months ended September 30, 2016 and 2015, respectively) Selling, General and Administrative Expense Depreciation and amortization Depreciation, Depletion and Amortization Total operating expenses Operating Expenses Income from operations Operating Income (Loss) Other income (expense), net Other Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax provision Income Tax Expense (Benefit) Net income Net Income (Loss) Attributable to Parent Income per common share: Earnings Per Share [Abstract] Basic (in dollars per share) Earnings Per Share, Basic Diluted (in dollars per share) Earnings Per Share, Diluted Weighted-average number of common shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Cash dividends declared per share: Dividends [Abstract] Common (in dollars per share) Common Stock, Dividends, Per Share, Declared Equity [Abstract] Dividends paid (in dollars per share) Common Stock, Dividends, Per Share, Cash Paid Dividends, cash Dividends, Cash Stock repurchase program, amount authorized Stock Repurchase Program, Authorized Amount Treasury stock, shares acquired (in shares) Treasury Stock, Shares, Acquired Treasury stock, value, acquired, cost method Treasury Stock, Value, Acquired, Cost Method Stock repurchase program, amounts available for future purchases Stock Repurchase Program, Remaining Authorized Repurchase Amount Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Guaranteed Insurance Contract, Type of Guarantee [Axis] Guaranteed Insurance Contract, Type of Guarantee [Axis] Guaranteed Insurance Contract, Type of Guarantee [Domain] Guaranteed Insurance Contract, Type of Guarantee [Domain] Korean Business Segment Korean Business Segment [Member] Represents Korean Business Segment. Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Noncurrent Assets Other Noncurrent Assets [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Securities Class Action Securities Class Action [Member] Securities Class Action [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Distributor claims reserve Distributor Claims Reserve Represents the funds which can be utilized to fund any outstanding distributor claims for product returns. Number of complaints Loss Contingency, New Claims Filed, Number COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Net income available to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net income allocated to common stockholders (in shares) Net income allocated to common stockholders (in dollars per share) Warrants to purchase common stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Non-vested restricted stock (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Net income allocated to common stockholders plus assumed conversions Net Income (Loss) Available to Common Stockholders, Diluted Net income allocated to common stockholders plus assumed conversions (in shares) Net income allocated to common stockholders plus assumed conversions (in dollars per share) STOCK-BASED COMPMENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Municipal Bonds and Notes Municipal Bonds and Notes [Member] Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments. Corporate Debt Securities Corporate Debt Securities [Member] Financial Institution Instruments Financial Institution Instruments [Member] Information pertaining to financial institution instruments. Debt Instrument [Line Items] Debt Instrument [Line Items] Adjusted Cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains (Losses) Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax Fair Value Available-for-sale Securities Subsequent Events [Abstract] SUBSEQUENT EVENT Subsequent Events [Text Block] Statement of Financial Position [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Treasury stock, shares Treasury Stock, Shares Related Party Transactions [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Broady Health Sciences Broady Health Sciences [Member] Represents Broady Health Sciences. Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Soothe Soothe [Member] Represents Soothe. ReStore ReStore [Member] Represents a product called ReStore™. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Royalty rate Royalty Rate Represents the royalty rate. Royalty expense Royalty Expense Number of days for termination notice Number Of Days Termination Notice Represents number of days termination notice. Statement of Comprehensive Income [Abstract] Net income Other comprehensive loss, net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Release of cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Net change in foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Unrealized (losses) gains on available-for-sale securities Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation Stock-based compensation Share-based Compensation Cumulative translation adjustment realized in net income Cumulative Translation Adjustment Realized In Net Income Represents cumulative translation adjustment realized in net income. Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories, net Increase (Decrease) in Inventories Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Income taxes payable Increase (Decrease) in Income Taxes Payable Accrued commissions Increase (Decrease) in Accrued Liabilities Other accrued expenses Increase (Decrease) in Other Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Amounts held in eWallets Increase (Decrease) in Customer Advances and Deposits Other current liabilities Increase (Decrease) in Other Current Liabilities Long-term incentive Increase (Decrease) in Deferred Compensation Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment, net Payments to Acquire Property, Plant, and Equipment Increase in restricted cash Increase (Decrease) in Restricted Cash Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of warrants Proceeds from Warrant Exercises Repurchase of common stock Payments for Repurchase of Common Stock Dividends paid Payments of Dividends Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION: Noncash Investing and Financing Items [Abstract] Conversion of Stock, Amount Converted Conversion of Stock, Amount Converted Issuance of treasury stock Stock Issued Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Equity Incentive Plan 2016 Equity Incentive 2016 Plan [Member] Equity Incentive 2016 Plan Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted Stock Restricted Stock [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based compensation expense Tax benefit attributable to stock-based compensation expense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Additional stock-based compensation expense Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost Shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based compensation expense not yet recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Recognition period for compensation costs not yet recognized (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Nonvested, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested, beginning balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Nonvested, ending balance (in dollars per share) Principles of Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Income Per Share Earnings Per Share, Policy [Policy Text Block] Recently Issued and Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock, cash dividends declared (in dollars per share) CommonStockSpecialDividendsPerShareDeclared CommonStockSpecialDividendsPerShareDeclared Special dividends declared during the period for each share of common stock outstanding. ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Accounts receivable Accounts Receivable, Net, Current Inventories, net Inventory, Net Other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Liabilities Liabilities [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Income taxes payable Accrued Income Taxes, Current Accrued commissions Accrued Liabilities, Current Other accrued expenses Other Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Deferred tax liability Deferred Tax Liabilities, Net, Current Amounts held in eWallets Other Deferred Credits, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term incentive Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2016 and December 31, 2015 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury stock, at cost; 1,692,218 and 840,202 shares at September 30, 2016 and December 31, 2015, respectively Treasury Stock, Value Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] CHINA CHINA Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Bank Deposit in Anticipation of Submitting Direct Selling License Application Bank Deposit in Anticipation of Submitting Direct Selling License Application [Member] Represents a bank deposit account in anticipation of submitting a direct selling license application. Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Repatriation of foreign earnings Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Warrants, number of securities called by warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Schedule of cash dividend activity Dividends Declared [Table Text Block] Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Available-for-sale Securities Available-for-sale Securities [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] AOCI Attributable to Parent AOCI Attributable to Parent [Member] Accumulated Foreign Currency Adjustment Attributable to Parent Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Net Investment Gain (Loss) Attributable to Parent Accumulated Net Investment Gain (Loss) Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Attributable to Parent [Abstract] Beginning balance Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Amounts reclassified out of accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Ending balance Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] Document And Entity Information Document Type Document Type Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Current Reporting Status Entity Current Reporting Status Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Sales returns Accrued Sales Returns Accrued Sales Returns Employee-related Employee-related Liabilities, Current Warehousing, inventory-related and other Accrued Warehousing And Inventory Related Expense Accrued Warehousing And Inventory Related Expense Total other accrued expenses EX-101.PRE 9 nhtc-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 nhtc20161025_10q_htm.xml IDEA: XBRL DOCUMENT 0000912061 2016-01-01 2016-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-09-30 0000912061 us-gaap:AccumulatedTranslationAdjustmentMember 2016-09-30 0000912061 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0000912061 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000912061 us-gaap:CashEquivalentsMember 2016-09-30 0000912061 2016-10-21 0000912061 us-gaap:CashEquivalentsMember 2015-12-31 0000912061 us-gaap:CashMember 2015-12-31 0000912061 us-gaap:CashMember 2016-09-30 0000912061 nhtc:BankDepositInAnticipationOfSubmittingDirectSellingLicenseApplicationMember 2015-09-30 0000912061 2016-01-01 2016-03-31 0000912061 nhtc:BankDepositInAnticipationOfSubmittingDirectSellingLicenseApplicationMember 2016-09-30 0000912061 2015-04-30 0000912061 country:CN 2016-09-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2016-09-30 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2015-12-31 0000912061 2016-09-30 0000912061 nhtc:FinancialInstitutionInstrumentsMember 2016-09-30 0000912061 nhtc:MunicipalBondsAndNotesMember 2016-09-30 0000912061 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000912061 nhtc:MunicipalBondsAndNotesMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-01-01 2016-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2016-09-30 0000912061 us-gaap:RestrictedStockMember nhtc:EquityIncentive2016PlanMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2015-12-31 0000912061 us-gaap:RestrictedStockMember 2016-09-30 0000912061 us-gaap:RestrictedStockMember 2016-01-01 2016-09-30 0000912061 2015-12-31 0000912061 nhtc:EquityIncentive2016PlanMember us-gaap:CommonStockMember 2016-04-07 0000912061 us-gaap:RestrictedStockMember 2016-04-08 2016-04-08 0000912061 2016-08-26 2016-08-26 0000912061 2016-03-24 2016-03-24 0000912061 2016-05-20 2016-05-20 0000912061 2016-01-12 0000912061 2015-07-28 0000912061 2015-01-01 2015-12-31 0000912061 us-gaap:OtherNoncurrentAssetsMember nhtc:KoreanBusinessSegmentMember 2016-09-30 0000912061 nhtc:SecuritiesClassActionMember 2016-01-01 2016-01-31 0000912061 2016-07-01 2016-09-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-09-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2013-02-01 2013-02-28 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-07-01 2016-09-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-09-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-04-29 2015-04-29 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2016-07-01 2016-09-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2015-07-01 2015-09-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-01-01 2015-09-30 0000912061 nhtc:ReStoreMember nhtc:BroadyHealthSciencesMember 2016-01-01 2016-09-30 0000912061 nhtc:SootheMember nhtc:BroadyHealthSciencesMember 2015-07-01 2015-09-30 0000912061 2015-01-01 2015-09-30 0000912061 us-gaap:SubsequentEventMember 2016-10-23 2016-10-23 0000912061 2015-07-01 2015-09-30 0000912061 2014-12-31 0000912061 2015-09-30 pure nhtc:complaint shares iso4217:USD iso4217:USD shares iso4217:CNY iso4217:KRW false --12-31 Q3 2016 0000912061 Yes Accelerated Filer 0.001 0.001 50000000 50000000 12979414 12979414 0 0 0 0 2 0.001 0.001 5000000 5000000 0 0 0 0 P3Y 840202 1692218 10-Q 2016-09-30 NATURAL HEALTH TRENDS CORP. 11287196 114500000 104914000 98000 57000 14842000 10455000 3540000 2286000 132980000 117712000 1297000 894000 1764000 1764000 3090000 3166000 723000 616000 139854000 124152000 3114000 2862000 655000 379000 18620000 19634000 18443000 16703000 4236000 4011000 60000 60000 19510000 16414000 1543000 1510000 66181000 61573000 4945000 5770000 71126000 67343000 0 0 13000 13000 86564000 85963000 24342000 -9647000 -302000 -101000 41889000 19419000 68728000 56809000 139854000 124152000 70679000 80779000 225416000 191204000 13627000 16001000 42966000 39025000 57052000 64778000 182450000 152179000 30578000 40036000 103547000 93443000 11170000 9867000 34505000 24571000 96000 72000 276000 181000 41844000 49975000 138328000 118195000 15208000 14803000 44122000 33984000 48000 -135000 40000 -112000 15256000 14668000 44162000 33872000 2699000 137000 8124000 330000 12557000 14531000 36038000 33542000 1.12 1.19 3.15 2.71 1.12 1.18 3.14 2.70 11209000 12239000 11437000 12364000 11232000 12284000 11463000 12439000 0.07 0.04 0.18 0.09 12557000 14531000 36038000 33542000 -54000 -118000 -329000 35000 0 0 -132000 82000 -54000 -118000 -197000 -47000 -11000 0 -4000 2000 12492000 14413000 35837000 33497000 36038000 33542000 276000 181000 94000 56000 -132000 82000 36000 217000 4382000 2904000 1208000 736000 91000 264000 252000 2140000 278000 190000 -1045000 11832000 3459000 8397000 222000 1844000 3098000 11354000 26000 93000 -825000 -229000 36288000 65197000 679000 645000 0 3028000 -679000 -3673000 0 309000 23704000 11079000 2049000 1111000 -25753000 -11881000 -270000 106000 9586000 49749000 104914000 44816000 114500000 94565000 7994000 152000 1741000 666000 NATURE OF OPERATIONS AND BASIS OF PRESENTATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Nature of Operations</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natural Health Trends Corp. (the ???Company???), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and ???quality of life??? products under the ???NHT Global??? brand. In most markets, the Company sells its products to a network of members referred to the Company by other members.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company???s wholly-owned subsidiaries have an active physical presence in the following markets: North America; Greater China, which consists of Hong Kong, Taiwan and China; South Korea; Singapore; Japan; and Europe. The Company also operates within certain Commonwealth of Independent States (Russia and Kazakhstan) through an engagement with a local service provider.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company???s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company???s 2015 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 4, 2016. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The most significant accounting estimates inherent in the preparation of the Company???s financial statements include estimates associated with obsolete inventory, the fair value of goodwill, revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company???s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include </span><span style="font-family:inherit;font-size:10pt;"><span>$5.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> held in banks located within China subject to foreign currency controls.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company???s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders??? equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,370</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104,914</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Cash</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2015, the Company funded a bank deposit account in the amount of CNY </span><span style="font-family:inherit;font-size:10pt;"><span>20 million</span></span><span style="font-family:inherit;font-size:10pt;"> (USD </span><span style="font-family:inherit;font-size:10pt;"><span>3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;">) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Accrued Expenses</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,215</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,088</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,087</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other accrued expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the nine months ended September 30, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its subsidiaries file income tax returns in the United States, various states, and foreign jurisdictions. The Company is no longer subject to U.S. federal income tax examinations for years prior to 2012, and is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Financial Instruments</span></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company???s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains (Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,785</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,029</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,024</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,556</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,556</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,370</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in accumulated other comprehensive loss by component for the first </span><span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of 2016 were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(329</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(333</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified out of accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, September 30, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(302</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company???s delivery to the carrier that completes delivery to the members, which is commonly referred to as ???F.O.B. Shipping Point.??? The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company???s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.</span></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales.  Event and training revenue is deferred and recognized as the event or training occurs. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Per Share</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted income per share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>88,087</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were exercised in April 2015.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables illustrates the computation of basic and diluted income per share for the periods indicated (in thousands, except per share data): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic EPS:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted EPS:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,557</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income<br/>(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares<br/>(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income<br/>(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares<br/>(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic EPS:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.71</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted EPS:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,038</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,463</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,542</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.70</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the nine months ended September 30, 2016, </span><span style="font-family:inherit;font-size:10pt;"><span>42,506</span></span><span style="font-family:inherit;font-size:10pt;"> shares of non-vested restricted stock were not included in the computation of diluted income per share as their effect would have been anti-dilutive. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued and Adopted Accounting Pronouncements</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standards Board (???FASB???) issued Accounting Standards Update (???ASU???) No. 2016-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, that requires organizations that lease assets, referred to as ???lessees???, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company???s present or future financial statements. The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>The most significant accounting estimates inherent in the preparation of the Company???s financial statements include estimates associated with obsolete inventory, the fair value of goodwill, revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company???s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected. 5800000 Additionally, as of <span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company???s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders??? equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices. Cash and cash equivalents at the end of each period were as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,370</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104,914</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 57130000 47431000 57370000 57483000 114500000 104914000 In June 2015, the Company funded a bank deposit account in the amount of CNY <span style="font-family:inherit;font-size:10pt;"><span>20 million</span></span><span style="font-family:inherit;font-size:10pt;"> (USD </span><span style="font-family:inherit;font-size:10pt;"><span>3.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span>) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund. 20000000 3000000.0 Other accrued expenses at the end of each period were as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,215</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,552</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,088</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,087</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other accrued expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,443</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 1215000 1552000 14140000 11064000 3088000 4087000 18443000 16703000 The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the nine months ended September 30, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company and its subsidiaries file income tax returns in the United States, various states, and foreign jurisdictions. The Company is no longer subject to U.S. federal income tax examinations for years prior to 2012, and is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries. 19800000 The carrying amounts of the Company???s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.</span></div><br/>Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits. Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 31, 2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains (Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,785</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,029</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,024</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,556</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,556</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,376</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,370</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,486</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,483</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 36785000 -3000 36782000 35222000 2000 35224000 7035000 -3000 7032000 5029000 -5000 5024000 13556000 0 13556000 17235000 0 17235000 57376000 -6000 57370000 57486000 -3000 57483000 The changes in accumulated other comprehensive loss by component for the first <span style="font-family:inherit;font-size:10pt;">nine</span><span style="font-family:inherit;font-size:10pt;"> months of 2016 were as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(329</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(333</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified out of accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, September 30, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(302</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div> -99000 -2000 -101000 -329000 -4000 -333000 132000 0 132000 -296000 -6000 -302000 Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company???s delivery to the carrier that completes delivery to the members, which is commonly referred to as ???F.O.B. Shipping Point.??? The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company???s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.</span></div><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales.  Event and training revenue is deferred and recognized as the event or training occurs. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority. Diluted income per share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares. 88087 The following tables illustrates the computation of basic and diluted income per share for the periods indicated (in thousands, except per share data): <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic EPS:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,557</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.19</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted EPS:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,557</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,284</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income<br/>(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares<br/>(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income<br/>(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares<br/>(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic EPS:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.71</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warrants to purchase common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">???</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted EPS:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,038</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,463</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,542</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.70</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 12557000 11209000 1.12 14531000 12239000 1.19 23000 45000 12557000 11232000 1.12 14531000 12284000 1.18 36038000 11437000 3.15 33542000 12364000 2.71 0 27000 26000 48000 36038000 11463000 3.14 33542000 12439000 2.70 42506 In March 2016, the Financial Accounting Standards Board (???FASB???) issued Accounting Standards Update (???ASU???) No. 2016-09, <span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements. </span><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, that requires organizations that lease assets, referred to as ???lessees???, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div>Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company???s present or future financial statements. STOCK-BASED COMPENSATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$10,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$21,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$94,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$56,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span><span style="font-family:inherit;font-size:10pt;">No</span><span style="font-family:inherit;font-size:10pt;"> tax benefits were attributed to the stock-based compensation because a valuation allowance was maintained for substantially all net deferred tax assets. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company???s 2016 annual meeting of stockholders. The modification of the award resulted in an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$64,000</span></span><span style="font-family:inherit;font-size:10pt;"> in stock-based compensation expense for the three months ended March 31, 2016.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Company???s annual meeting of stockholders held on April 7, 2016, the Company???s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the ???2016 Plan???) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company???s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company???s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 8, 2016, the Company initially granted </span><span style="font-family:inherit;font-size:10pt;"><span>51,015</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2015 performance incentives. The shares vest on a quarterly basis over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years and are subject to forfeiture in the event of the employee???s termination of service to the Company under specified circumstances. </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company???s restricted stock activity under the 2016 Plan:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,015</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at September 30, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company???s other restricted stock activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,773</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at September 30, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,939</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;">, total unrecognized stock-based compensation expense related to non-vested restricted stock was </span><span style="font-family:inherit;font-size:10pt;"><span>$49,000</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>1.3 years</span></span>. 10000 21000 94000 56000 64000 2500000 51015 0 0 51015 34.13 8509 34.13 42506 34.13 The following table summarizes the Company???s other restricted stock activity:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44,712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16,773</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at September 30, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,939</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div>The following table summarizes the Company???s restricted stock activity under the 2016 Plan:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>???</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51,015</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8,509</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at September 30, 2016</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div> 44712 12.15 0 0 16773 12.15 27939 12.15 49000 P1Y3M18D STOCKHOLDERS??? EQUITY<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company???s cash dividend activity for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 19, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 16, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 26, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 21, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 10, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 20, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 16, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 24, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Treasury Stock</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Board of Directors authorized an increase to the Company???s stock repurchase program first approved on July 28, 2015 from </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Repurchases are expected to be executed to the extent that the Company???s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">During February 2016, pursuant to the stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company???s common stock in the open market. During the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</span><span style="font-family:inherit;font-size:10pt;">, the Company purchased a total of </span><span style="font-family:inherit;font-size:10pt;"><span>903,031</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus transaction costs. Pursuant to the Company???s stock repurchase program first approved on July 28, 2015, the Company purchased a total of </span><span style="font-family:inherit;font-size:10pt;"><span>268,706</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the year ended December 31, 2015. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span> stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax. The following table summarizes the Company???s cash dividend activity for the <span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">July 19, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 16, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 26, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 21, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 10, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 20, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 1, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.05</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>576</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 16, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 24, 2016</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div> 0.07 787000 0.06 686000 0.05 576000 0.18 2049000 15000000.0 70000000.0 903031 23700000 268706 10000000.0 32000000.0 70000000.0 COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Consumer Indemnity</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As required by the Door-to-Door Sales Act in South Korea, the Company maintains insurance for consumer indemnity claims with a mutual aid cooperative by possessing a mutual aid contract with Mutual Aid Cooperative & Consumer (the ???Cooperative???). The contract secures payment to members in the event that the Company is unable to provide refunds to members. Typically, requests for refunds are paid directly by the Company according to the Company???s normal Korean refund policy, which requires that refund requests be submitted within three months. Accordingly, the Company estimates and accrues a reserve for product returns based on this policy and its historical experience. Depending on the sales volume, the Company may be required to increase or decrease the amount of the contract. The maximum potential amount of future payments the Company could be required to make to address actual member claims under the contract is equivalent to three months of rolling sales. At </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;">, non-current other assets include KRW </span><span style="font-family:inherit;font-size:10pt;"><span>223 million</span></span><span style="font-family:inherit;font-size:10pt;"> (USD </span><span style="font-family:inherit;font-size:10pt;"><span>$203,000</span></span><span style="font-family:inherit;font-size:10pt;">) underlying the contract, which can be utilized by the Cooperative to fund any outstanding member claims. The Company believes that the likelihood of utilizing these funds to provide for members claims is remote.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Class Action</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> purported securities class action complaints were filed against the Company and its top executives. On March 29, 2016, the court consolidated the purported securities class actions, appointed two Lead Plaintiffs, Messrs. Dao and Juan, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class in the consolidated action. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of certain of our stockholders under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., Chris T. Sharng, and Timothy S. Davidson, and to assert claims under Section 20(a) of the Securities Exchange Act of 1934 against Chris T. Sharng, Timothy S. Davidson, and George K. Broady. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company filed a motion to dismiss the consolidated complaint on June 15, 2016 and a reply in support of its motion to dismiss on August 22, 2016. The Court has not ruled on the Company???s motion to dismiss yet. The Company believes that these claims are without merit and intends to vigorously defend against the allegations in the consolidated complaint.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Derivative Claim</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou v. Sharng</span><span style="font-family:inherit;font-size:10pt;">. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt v. Sharng</span><span style="font-family:inherit;font-size:10pt;"> (collectively the ???Derivative Complaints???). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company???s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. The derivative cases have been stayed pending the resolution of the motion to dismiss in the securities class action, and the defendants have not yet filed a response. Nevertheless, the defendants believe that these claims are without merit and intend to vigorously defend against the allegations in these derivative actions.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated class action and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company???s operating results and financial condition. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Claims</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company is currently in the early stages of a legal matter that involves one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company???s vendor. 223000000 203000 RELATED PARTY TRANSACTIONS<div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Product Royalties</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (???BHS???) regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Soothe</span><span style="font-family:inherit;font-size:10pt;">???. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Royalties recognized for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$700</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,300</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2,700</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5,200</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">??? notice. Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ReStor???.</span><span style="font-family:inherit;font-size:10pt;">  Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were </span><span style="font-family:inherit;font-size:10pt;"><span>$106,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$154,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$386,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$410,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2015</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">??? notice or, under certain circumstances, with </span><span style="font-family:inherit;font-size:10pt;">no</span> notice. Otherwise, the agreement terminates March 31, 2020. 0.025 700 1300 2700 5200 P120DT0H 0.025 106000 154000 386000 410000 P120DT0H SUBSEQUENT EVENT<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">October 23, 2016</span><span style="font-family:inherit;font-size:10pt;">, the Board of Directors declared a quarterly cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.08</span></span><span style="font-family:inherit;font-size:10pt;"> and a special cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.35</span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. Such dividends are payable on </span><span style="font-family:inherit;font-size:10pt;">November 25, 2016</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on </span><span style="font-family:inherit;font-size:10pt;">November 15, 2016</span>. Payment of any future dividends on shares of common stock will be at the discretion of the Company???s Board of Directors. 0.08 0.35 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2016
Oct. 21, 2016
Document And Entity Information    
Document Type 10-Q  
Document Period End Date Sep. 30, 2016  
Entity Registrant Name NATURAL HEALTH TRENDS CORP.  
Entity Central Index Key 0000912061  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Current Reporting Status Yes  
Entity Common Stock, Shares Outstanding (in shares)   11,287,196
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 114,500 $ 104,914
Accounts receivable 98 57
Inventories, net 14,842 10,455
Other current assets 3,540 2,286
Total current assets 132,980 117,712
Property and equipment, net 1,297 894
Goodwill 1,764 1,764
Restricted cash 3,090 3,166
Other assets 723 616
Total assets 139,854 124,152
Current liabilities:    
Accounts payable 3,114 2,862
Income taxes payable 655 379
Accrued commissions 18,620 19,634
Other accrued expenses 18,443 16,703
Deferred revenue 4,236 4,011
Deferred tax liability 60 60
Amounts held in eWallets 19,510 16,414
Other current liabilities 1,543 1,510
Total current liabilities 66,181 61,573
Long-term incentive 4,945 5,770
Total liabilities 71,126 67,343
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding 0 0
Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2016 and December 31, 2015 13 13
Additional paid-in capital 86,564 85,963
Retained earnings (accumulated deficit) 24,342 (9,647)
Accumulated other comprehensive loss (302) (101)
Treasury stock, at cost; 1,692,218 and 840,202 shares at September 30, 2016 and December 31, 2015, respectively (41,889) (19,419)
Total stockholders’ equity 68,728 56,809
Total liabilities and stockholders’ equity $ 139,854 $ 124,152
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Sep. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 12,979,414 12,979,414
Treasury stock, shares 1,692,218 840,202
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Net sales $ 70,679 $ 80,779 $ 225,416 $ 191,204
Cost of sales 13,627 16,001 42,966 39,025
Gross profit 57,052 64,778 182,450 152,179
Operating expenses:        
Commissions expense 30,578 40,036 103,547 93,443
Selling, general and administrative expenses (including stock-based compensation expense of $10 and $21 during the three months ended September 30, 2016 and 2015, respectively, and $94 and $56 during the nine months ended September 30, 2016 and 2015, respectively) 11,170 9,867 34,505 24,571
Depreciation and amortization 96 72 276 181
Total operating expenses 41,844 49,975 138,328 118,195
Income from operations 15,208 14,803 44,122 33,984
Other income (expense), net 48 (135) 40 (112)
Income before income taxes 15,256 14,668 44,162 33,872
Income tax provision 2,699 137 8,124 330
Net income $ 12,557 $ 14,531 $ 36,038 $ 33,542
Income per common share:        
Basic (in dollars per share) $ 1.12 $ 1.19 $ 3.15 $ 2.71
Diluted (in dollars per share) $ 1.12 $ 1.18 $ 3.14 $ 2.70
Weighted-average number of common shares outstanding:        
Basic (in shares) 11,209 12,239 11,437 12,364
Diluted (in shares) 11,232 12,284 11,463 12,439
Cash dividends declared per share:        
Common (in dollars per share) $ 0.07 $ 0.04 $ 0.18 $ 0.09
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Income Statement [Abstract]        
Stock-based compensation expense included in selling, general, and administrative expense $ 10 $ 21 $ 94 $ 56
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Statement of Comprehensive Income [Abstract]        
Net income $ 12,557 $ 14,531 $ 36,038 $ 33,542
Other comprehensive loss, net of tax:        
Foreign currency translation adjustment (54) (118) (329) 35
Release of cumulative translation adjustment 0 0 132 (82)
Net change in foreign currency translation adjustment (54) (118) (197) (47)
Unrealized (losses) gains on available-for-sale securities (11) 0 (4) 2
Comprehensive income $ 12,492 $ 14,413 $ 35,837 $ 33,497
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income $ 36,038 $ 33,542
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 276 181
Stock-based compensation 94 56
Cumulative translation adjustment realized in net income 132 (82)
Changes in assets and liabilities:    
Accounts receivable (36) (217)
Inventories, net (4,382) (2,904)
Other current assets (1,208) (736)
Other assets (91) (264)
Accounts payable 252 2,140
Income taxes payable 278 190
Accrued commissions (1,045) 11,832
Other accrued expenses 3,459 8,397
Deferred revenue 222 1,844
Amounts held in eWallets 3,098 11,354
Other current liabilities 26 93
Long-term incentive (825) (229)
Net cash provided by operating activities 36,288 65,197
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment, net (679) (645)
Increase in restricted cash 0 (3,028)
Net cash used in investing activities (679) (3,673)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of warrants 0 309
Repurchase of common stock (23,704) (11,079)
Dividends paid (2,049) (1,111)
Net cash used in financing activities (25,753) (11,881)
Effect of exchange rates on cash and cash equivalents (270) 106
Net increase in cash and cash equivalents 9,586 49,749
CASH AND CASH EQUIVALENTS, beginning of period 104,914 44,816
CASH AND CASH EQUIVALENTS, end of period 114,500 94,565
SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:    
Conversion of Stock, Amount Converted 7,994 152
Issuance of treasury stock $ 1,741 $ 666
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
NATURE OF OPERATIONS AND BASIS OF PRESENTATION
9 Months Ended
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS AND BASIS OF PRESENTATION NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Nature of Operations 
 
Natural Health Trends Corp. (the “Company”), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and “quality of life” products under the “NHT Global” brand. In most markets, the Company sells its products to a network of members referred to the Company by other members.
 
The Company’s wholly-owned subsidiaries have an active physical presence in the following markets: North America; Greater China, which consists of Hong Kong, Taiwan and China; South Korea; Singapore; Japan; and Europe. The Company also operates within certain Commonwealth of Independent States (Russia and Kazakhstan) through an engagement with a local service provider.

Basis of Presentation 
 
The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s 2015 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 4, 2016.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 
Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
 
Use of Estimates 
 
The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.
 
The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with obsolete inventory, the fair value of goodwill, revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.

Cash and Cash Equivalents
 
As of September 30, 2016, cash and cash equivalents include $5.8 million held in banks located within China subject to foreign currency controls.
 
Additionally, as of September 30, 2016, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2016 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.
 
Cash and cash equivalents at the end of each period were as follows (in thousands):
 
September 30, 2016
 
December 31, 2015
Cash
$
57,130

 
$
47,431

Cash equivalents
57,370

 
57,483

Total cash and cash equivalents
$
114,500

 
$
104,914



Restricted Cash
 
In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million (USD 3.0 million at September 30, 2016) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.

Other Accrued Expenses
 
Other accrued expenses at the end of each period were as follows (in thousands):
 
September 30, 2016
 
December 31, 2015
Sales returns
$
1,215

 
$
1,552

Employee-related
14,140

 
11,064

Warehousing, inventory-related and other
3,088

 
4,087

Total other accrued expenses
$
18,443

 
$
16,703



Income Taxes
 
The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the nine months ended September 30, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate.

The Company and its subsidiaries file income tax returns in the United States, various states, and foreign jurisdictions. The Company is no longer subject to U.S. federal income tax examinations for years prior to 2012, and is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.
 
Fair Value of Financial Instruments
 
The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
September 30, 2016
 
December 31, 2015
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains (Losses)
 
Fair Value
Municipal bonds and notes
$
36,785

 
$
(3
)
 
$
36,782

 
$
35,222

 
$
2

 
$
35,224

Corporate debt securities
7,035

 
(3
)
 
7,032

 
5,029

 
(5
)
 
5,024

Financial institution instruments
13,556

 

 
13,556

 
17,235

 

 
17,235

Total available-for-sale investments
$
57,376

 
$
(6
)
 
$
57,370

 
$
57,486

 
$
(3
)
 
$
57,483


 
Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.
 
Accumulated Other Comprehensive Loss
 
The changes in accumulated other comprehensive loss by component for the first nine months of 2016 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2015
$
(99
)
 
$
(2
)
 
$
(101
)
Other comprehensive loss
(329
)
 
(4
)
 
(333
)
Amounts reclassified out of accumulated other comprehensive loss
132

 

 
132

Balance, September 30, 2016
$
(296
)
 
$
(6
)
 
$
(302
)

 
Revenue Recognition
 
Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.
 
Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.
 
Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales.  Event and training revenue is deferred and recognized as the event or training occurs.
 
Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
 
Income Per Share

Diluted income per share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.

Warrants to purchase 88,087 shares of common stock were exercised in April 2015.
 
The following tables illustrates the computation of basic and diluted income per share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended September 30,
 
2016
 
2015
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
12,557

 
11,209

 
$
1.12

 
$
14,531

 
12,239

 
$
1.19

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
23

 
 

 

 
45

 
 

Diluted EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
12,557

 
11,232

 
$
1.12

 
$
14,531

 
12,284

 
$
1.18

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30,
 
2016
 
2015
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
36,038

 
11,437

 
$
3.15

 
$
33,542

 
12,364

 
$
2.71

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Warrants to purchase common stock

 

 
 

 

 
27

 
 

Non-vested restricted stock

 
26

 
 

 

 
48

 
 

Diluted EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
36,038

 
11,463

 
$
3.14

 
$
33,542

 
12,439

 
$
2.70



For the nine months ended September 30, 2016, 42,506 shares of non-vested restricted stock were not included in the computation of diluted income per share as their effect would have been anti-dilutive.

Recently Issued and Adopted Accounting Pronouncements
 
In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 
Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK-BASED COMPMENSATION
9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
STOCK-BASED COMPMENSATION STOCK-BASED COMPENSATION
 
Stock-based compensation expense totaled $10,000 and $21,000 for the three months ended September 30, 2016 and 2015, respectively, and $94,000 and $56,000 for the nine months ended September 30, 2016 and 2015, respectively. No tax benefits were attributed to the stock-based compensation because a valuation allowance was maintained for substantially all net deferred tax assets. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company’s 2016 annual meeting of stockholders. The modification of the award resulted in an additional $64,000 in stock-based compensation expense for the three months ended March 31, 2016.

At the Company’s annual meeting of stockholders held on April 7, 2016, the Company’s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the “2016 Plan”) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units stock appreciation rights and other similar equity-based awards to the Company’s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to 2,500,000 shares of the Company’s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted.

On April 8, 2016, the Company initially granted 51,015 shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2015 performance incentives. The shares vest on a quarterly basis over three years and are subject to forfeiture in the event of the employee’s termination of service to the Company under specified circumstances.

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015

 
$

Granted
51,015

 
34.13

Vested
(8,509
)
 
34.13

Nonvested at September 30, 2016
42,506

 
34.13



The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015
44,712

 
$
12.15

Granted

 

Vested
(16,773
)
 
12.15

Nonvested at September 30, 2016
27,939

 
12.15


 
As of September 30, 2016, total unrecognized stock-based compensation expense related to non-vested restricted stock was $49,000, which is expected to be recognized over a weighted-average period of 1.3 years.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY
9 Months Ended
Sep. 30, 2016
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
 
Dividends
 
The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2016 (in thousands, except per share data):

Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
July 19, 2016
 
$
0.07

 
$
787

 
August 16, 2016
 
August 26, 2016
April 21, 2016
 
$
0.06

 
$
686

 
May 10, 2016
 
May 20, 2016
March 1, 2016
 
$
0.05

 
$
576

 
March 16, 2016
 
March 24, 2016
 
 
$
0.18

 
$
2,049

 
 
 
 


Treasury Stock

On January 12, 2016, the Board of Directors authorized an increase to the Company’s stock repurchase program first approved on July 28, 2015 from $15.0 million to $70.0 million. Repurchases are expected to be executed to the extent that the Company’s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued.

During February 2016, pursuant to the stock repurchase program, the Company authorized its broker to proceed with the purchase of shares of the Company’s common stock in the open market. During the nine months ended September 30, 2016, the Company purchased a total of 903,031 shares of its common stock for an aggregate purchase price of $23.7 million, plus transaction costs. Pursuant to the Company’s stock repurchase program first approved on July 28, 2015, the Company purchased a total of 268,706 shares of its common stock for an aggregate purchase price of $10.0 million during the year ended December 31, 2015. As of September 30, 2016, $32.0 million of the $70.0 million stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
COMMITMENTS AND CONTINGENCIES
9 Months Ended
Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES

Consumer Indemnity

As required by the Door-to-Door Sales Act in South Korea, the Company maintains insurance for consumer indemnity claims with a mutual aid cooperative by possessing a mutual aid contract with Mutual Aid Cooperative & Consumer (the “Cooperative”). The contract secures payment to members in the event that the Company is unable to provide refunds to members. Typically, requests for refunds are paid directly by the Company according to the Company’s normal Korean refund policy, which requires that refund requests be submitted within three months. Accordingly, the Company estimates and accrues a reserve for product returns based on this policy and its historical experience. Depending on the sales volume, the Company may be required to increase or decrease the amount of the contract. The maximum potential amount of future payments the Company could be required to make to address actual member claims under the contract is equivalent to three months of rolling sales. At September 30, 2016, non-current other assets include KRW 223 million (USD $203,000) underlying the contract, which can be utilized by the Cooperative to fund any outstanding member claims. The Company believes that the likelihood of utilizing these funds to provide for members claims is remote.

Securities Class Action

In January 2016, two purported securities class action complaints were filed against the Company and its top executives. On March 29, 2016, the court consolidated the purported securities class actions, appointed two Lead Plaintiffs, Messrs. Dao and Juan, and appointed the Rosen Law Firm and Levi & Korsinsky LLP as co-Lead Counsel for the purported class in the consolidated action. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of certain of our stockholders under Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., Chris T. Sharng, and Timothy S. Davidson, and to assert claims under Section 20(a) of the Securities Exchange Act of 1934 against Chris T. Sharng, Timothy S. Davidson, and George K. Broady. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company filed a motion to dismiss the consolidated complaint on June 15, 2016 and a reply in support of its motion to dismiss on August 22, 2016. The Court has not ruled on the Company’s motion to dismiss yet. The Company believes that these claims are without merit and intends to vigorously defend against the allegations in the consolidated complaint.

Shareholder Derivative Claim

In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: Zhou v. Sharng. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: Kleinfeldt v. Sharng (collectively the “Derivative Complaints”). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company’s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. The derivative cases have been stayed pending the resolution of the motion to dismiss in the securities class action, and the defendants have not yet filed a response. Nevertheless, the defendants believe that these claims are without merit and intend to vigorously defend against the allegations in these derivative actions.

The consolidated class action and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company’s operating results and financial condition.

Other Claims

The Company is currently in the early stages of a legal matter that involves one of its vendors and an outside party. Per the royalty agreement with the vendor, the Company believes that it is fully indemnified in the event of an unfavorable outcome and any potential settlement costs related to the matter would be fully covered by the Company’s vendor.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
RELATED PARTY TRANSACTIONS
9 Months Ended
Sep. 30, 2016
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS

Product Royalties

On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (“BHS”) regarding the manufacture and sale of a product called Soothe™. George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS. Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide. Royalties recognized for the three months ended September 30, 2016 and 2015 were $700 and $1,300, respectively, and $2,700 and $5,200 for the nine months ended September 30, 2016 and 2015, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice. Otherwise, the agreement terminates March 31, 2020.

In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called ReStor™.  Under the agreement, the Company agreed to pay BHS a royalty of 2.5% of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue. Such provision was effective retroactively to January 1, 2015. Such royalties were $106,000 and $154,000 for the three months ended September 30, 2016 and 2015, respectively, and $386,000 and $410,000 for the nine months ended September 30, 2016 and 2015, respectively. The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on 120 days’ notice or, under certain circumstances, with no notice. Otherwise, the agreement terminates March 31, 2020.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUBSEQUENT EVENT
9 Months Ended
Sep. 30, 2016
Subsequent Events [Abstract]  
SUBSEQUENT EVENT SUBSEQUENT EVENT
 
On October 23, 2016, the Board of Directors declared a quarterly cash dividend of $0.08 and a special cash dividend of $0.35 on each share of common stock outstanding. Such dividends are payable on November 25, 2016 to stockholders of record on November 15, 2016. Payment of any future dividends on shares of common stock will be at the discretion of the Company’s Board of Directors.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Principles of Consolidation The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.
Use of Estimates The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period.
 
The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates associated with obsolete inventory, the fair value of goodwill, revenue recognition, as well as those used in the determination of liabilities related to sales returns, commissions and income taxes. Various assumptions and other factors prompt the determination of these significant estimates. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. The actual results may differ materially and adversely from the Company’s estimates. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.
Cash and Cash Equivalents Additionally, as of September 30, 2016, cash and cash equivalents include the Company’s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.  Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, Investments - Debt and Equity Securities. As such, the Company determined its investments in debt securities held at September 30, 2016 should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders’ equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.
Restricted Cash In June 2015, the Company funded a bank deposit account in the amount of CNY 20 million (USD 3.0 million at September 30, 2016) in anticipation of submitting a direct selling license application in China. Such deposit is required by Chinese laws to establish a consumer protection fund.
Income Taxes The Company recognizes income taxes under the liability method of accounting for income taxes. Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory tax rates in effect for the years in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution.  The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense.  Deferred taxes are not provided on the portion of undistributed earnings of subsidiaries outside of the United States when these earnings are considered permanently reinvested.

As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries. The Company repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses. Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced. The excess amount repatriated during the nine months ended September 30, 2016 was generated from current foreign earnings. The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate.

The Company and its subsidiaries file income tax returns in the United States, various states, and foreign jurisdictions. The Company is no longer subject to U.S. federal income tax examinations for years prior to 2012, and is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.
Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.
 
Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.  The Company has elected to not fair value existing eligible items.

Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.
Revenue Recognition Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon the Company’s delivery to the carrier that completes delivery to the members, which is commonly referred to as “F.O.B. Shipping Point.” The Company primarily receives payment by credit card at the time members place orders. Amounts received for unshipped product are recorded as deferred revenue. The Company’s sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return.
 
Actual product returns are recorded as a reduction to net sales. The Company estimates and accrues a reserve for product returns based on its return policies and historical experience.
 
Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal.
 
Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales.  Event and training revenue is deferred and recognized as the event or training occurs.
 
Various taxes on the sale of products and enrollment packages to members are collected by the Company as an agent and remitted to the respective taxing authority. These taxes are presented on a net basis and recorded as a liability until remitted to the respective taxing authority.
Income Per Share Diluted income per share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock and warrants is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.
Recently Issued and Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-09, Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, Leases, that requires organizations that lease assets, referred to as “lessees”, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
 
Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company’s present or future financial statements.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2016
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents Cash and cash equivalents at the end of each period were as follows (in thousands):
 
September 30, 2016
 
December 31, 2015
Cash
$
57,130

 
$
47,431

Cash equivalents
57,370

 
57,483

Total cash and cash equivalents
$
114,500

 
$
104,914

Schedule of Accrued Expenses Other accrued expenses at the end of each period were as follows (in thousands):
 
September 30, 2016
 
December 31, 2015
Sales returns
$
1,215

 
$
1,552

Employee-related
14,140

 
11,064

Warehousing, inventory-related and other
3,088

 
4,087

Total other accrued expenses
$
18,443

 
$
16,703

Available-for-sale Securities Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):
 
September 30, 2016
 
December 31, 2015
 
Adjusted Cost
 
Gross Unrealized Losses
 
Fair Value
 
Adjusted Cost
 
Gross Unrealized Gains (Losses)
 
Fair Value
Municipal bonds and notes
$
36,785

 
$
(3
)
 
$
36,782

 
$
35,222

 
$
2

 
$
35,224

Corporate debt securities
7,035

 
(3
)
 
7,032

 
5,029

 
(5
)
 
5,024

Financial institution instruments
13,556

 

 
13,556

 
17,235

 

 
17,235

Total available-for-sale investments
$
57,376

 
$
(6
)
 
$
57,370

 
$
57,486

 
$
(3
)
 
$
57,483

Schedule of Accumulated Other Comprehensive Income (Loss) The changes in accumulated other comprehensive loss by component for the first nine months of 2016 were as follows (in thousands):
 
Foreign Currency Translation Adjustment
 
Unrealized Losses on Available-For-Sale Investments
 
Total
Balance, December 31, 2015
$
(99
)
 
$
(2
)
 
$
(101
)
Other comprehensive loss
(329
)
 
(4
)
 
(333
)
Amounts reclassified out of accumulated other comprehensive loss
132

 

 
132

Balance, September 30, 2016
$
(296
)
 
$
(6
)
 
$
(302
)
Schedule of Earnings Per Share, Basic and Diluted The following tables illustrates the computation of basic and diluted income per share for the periods indicated (in thousands, except per share data): 
 
Three Months Ended September 30,
 
2016
 
2015
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
12,557

 
11,209

 
$
1.12

 
$
14,531

 
12,239

 
$
1.19

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Non-vested restricted stock

 
23

 
 

 

 
45

 
 

Diluted EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
12,557

 
11,232

 
$
1.12

 
$
14,531

 
12,284

 
$
1.18

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nine Months Ended September 30,
 
2016
 
2015
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
 
Income
(Numerator)
 
Shares
(Denominator)
 
Per Share Amount
Basic EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders
$
36,038

 
11,437

 
$
3.15

 
$
33,542

 
12,364

 
$
2.71

Effect of dilutive securities:
 
 
 
 
 
 
 
 
 
 
 
Warrants to purchase common stock

 

 
 

 

 
27

 
 

Non-vested restricted stock

 
26

 
 

 

 
48

 
 

Diluted EPS:
 
 
 
 
 
 
 
 
 
 
 
Net income available to common stockholders plus assumed conversions
$
36,038

 
11,463

 
$
3.14

 
$
33,542

 
12,439

 
$
2.70

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK-BASED COMPMENSATION (Tables)
9 Months Ended
Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Summary of Restricted Stock Activity The following table summarizes the Company’s other restricted stock activity:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015
44,712

 
$
12.15

Granted

 

Vested
(16,773
)
 
12.15

Nonvested at September 30, 2016
27,939

 
12.15

The following table summarizes the Company’s restricted stock activity under the 2016 Plan:
 
Shares
 
Wtd. Avg. Price at Date of Issuance
Nonvested at December 31, 2015

 
$

Granted
51,015

 
34.13

Vested
(8,509
)
 
34.13

Nonvested at September 30, 2016
42,506

 
34.13

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY (Tables)
9 Months Ended
Sep. 30, 2016
Equity [Abstract]  
Schedule of cash dividend activity The following table summarizes the Company’s cash dividend activity for the nine months ended September 30, 2016 (in thousands, except per share data):

Declaration Date
 
Per Share
 
Amount
 
Record Date
 
Payment Date
July 19, 2016
 
$
0.07

 
$
787

 
August 16, 2016
 
August 26, 2016
April 21, 2016
 
$
0.06

 
$
686

 
May 10, 2016
 
May 20, 2016
March 1, 2016
 
$
0.05

 
$
576

 
March 16, 2016
 
March 24, 2016
 
 
$
0.18

 
$
2,049

 
 
 
 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NARRATIVE (Details)
$ in Thousands, ¥ in Millions
3 Months Ended
Mar. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2015
CNY (¥)
Apr. 30, 2015
shares
Dec. 31, 2014
USD ($)
Cash and Cash Equivalents [Line Items]              
Cash and cash equivalents   $ 114,500 $ 104,914 $ 94,565     $ 44,816
Repatriation of foreign earnings $ 19,800            
Warrants, number of securities called by warrants | shares           88,087  
Bank Deposit in Anticipation of Submitting Direct Selling License Application              
Cash and Cash Equivalents [Line Items]              
Restricted cash and cash equivalents   3,000     ¥ 20    
CHINA              
Cash and Cash Equivalents [Line Items]              
Cash and cash equivalents   $ 5,800          
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CASH AND CASH EQUIVALENTS (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Sep. 30, 2015
Dec. 31, 2014
Cash and Cash Equivalents [Line Items]        
Document Period End Date Sep. 30, 2016      
Cash and cash equivalents $ 114,500 $ 104,914 $ 94,565 $ 44,816
Cash        
Cash and Cash Equivalents [Line Items]        
Cash and cash equivalents 57,130 47,431    
Cash Equivalents        
Cash and Cash Equivalents [Line Items]        
Cash and cash equivalents $ 57,370 $ 57,483    
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - OTHER ACCRUED EXPENSES (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Accounting Policies [Abstract]    
Document Period End Date Sep. 30, 2016  
Sales returns $ 1,215 $ 1,552
Employee-related 14,140 11,064
Warehousing, inventory-related and other 3,088 4,087
Total other accrued expenses $ 18,443 $ 16,703
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - AVAILABLE-FOR-SALE INVESTMENTS (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2016
Dec. 31, 2015
Debt Instrument [Line Items]    
Document Period End Date Sep. 30, 2016  
Adjusted Cost $ 57,376 $ 57,486
Gross Unrealized Gains (Losses) (6) (3)
Fair Value 57,370 57,483
Municipal Bonds and Notes    
Debt Instrument [Line Items]    
Adjusted Cost 36,785 35,222
Gross Unrealized Gains (Losses) (3) 2
Fair Value 36,782 35,224
Corporate Debt Securities    
Debt Instrument [Line Items]    
Adjusted Cost 7,035 5,029
Gross Unrealized Gains (Losses) (3) (5)
Fair Value 7,032 5,024
Financial Institution Instruments    
Debt Instrument [Line Items]    
Adjusted Cost 13,556 17,235
Gross Unrealized Gains (Losses) 0 0
Fair Value $ 13,556 $ 17,235
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CHANGES IN ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2016
USD ($)
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance $ 56,809
Ending balance 68,728
AOCI Attributable to Parent  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (101)
Other comprehensive loss (333)
Amounts reclassified out of accumulated other comprehensive loss 132
Ending balance (302)
Accumulated Foreign Currency Adjustment Attributable to Parent  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (99)
Other comprehensive loss (329)
Amounts reclassified out of accumulated other comprehensive loss 132
Ending balance (296)
Accumulated Net Investment Gain (Loss) Attributable to Parent  
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]  
Beginning balance (2)
Other comprehensive loss (4)
Amounts reclassified out of accumulated other comprehensive loss 0
Ending balance $ (6)
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - BASIC AND DILUTED EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Accounting Policies [Abstract]        
Document Period End Date     Sep. 30, 2016  
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount     42,506  
Net income available to common stockholders $ 12,557 $ 14,531 $ 36,038 $ 33,542
Net income allocated to common stockholders (in shares) 11,209,000 12,239,000 11,437,000 12,364,000
Net income allocated to common stockholders (in dollars per share) $ 1.12 $ 1.19 $ 3.15 $ 2.71
Warrants to purchase common stock (in shares)     0 27,000
Non-vested restricted stock (in shares) 23,000 45,000 26,000 48,000
Net income allocated to common stockholders plus assumed conversions $ 12,557 $ 14,531 $ 36,038 $ 33,542
Net income allocated to common stockholders plus assumed conversions (in shares) 11,232,000 12,284,000 11,463,000 12,439,000
Net income allocated to common stockholders plus assumed conversions (in dollars per share) $ 1.12 $ 1.18 $ 3.14 $ 2.70
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK-BASED COMPMENSATION - NARRATIVE (Details) - USD ($)
3 Months Ended 9 Months Ended
Apr. 08, 2016
Sep. 30, 2016
Mar. 31, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Apr. 07, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Share-based compensation expense   $ 10,000   $ 21,000 $ 94,000 $ 56,000  
Tax benefit attributable to stock-based compensation expense   0   $ 0 $ 0 $ 0  
Additional stock-based compensation expense     $ 64,000        
Restricted Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Granted (in shares) 51,015       0    
Award vesting period (in years) 3 years            
Share-based compensation expense not yet recognized   $ 49,000     $ 49,000    
Recognition period for compensation costs not yet recognized (in years)         1 year 3 months 18 days    
Equity Incentive Plan 2016 | Common Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares authorized             2,500,000
Equity Incentive Plan 2016 | Restricted Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Granted (in shares)         51,015    
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCK-BASED COMPMENSATION - RESTRICTED STOCK ACTIVITY (Details) - Restricted Stock - $ / shares
9 Months Ended
Apr. 08, 2016
Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Nonvested, beginning balance (in shares)   44,712
Granted (in shares) 51,015 0
Vested (in shares)   (16,773)
Nonvested, ending balance (in shares)   27,939
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Nonvested, beginning balance (in dollars per share)   $ 12.15
Granted (in dollars per share)   0
Vested (in dollars per share)   12.15
Nonvested, ending balance (in dollars per share)   $ 12.15
Equity Incentive Plan 2016    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Nonvested, beginning balance (in shares)   0
Granted (in shares)   51,015
Vested (in shares)   (8,509)
Nonvested, ending balance (in shares)   42,506
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Nonvested, beginning balance (in dollars per share)   $ 0
Granted (in dollars per share)   34.13
Vested (in dollars per share)   34.13
Nonvested, ending balance (in dollars per share)   $ 34.13
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY - NARRATIVE (Detail) - USD ($)
9 Months Ended 12 Months Ended
Aug. 26, 2016
May 20, 2016
Mar. 24, 2016
Sep. 30, 2016
Dec. 31, 2015
Jan. 12, 2016
Jul. 28, 2015
Equity [Abstract]              
Dividends paid (in dollars per share) $ 0.07 $ 0.06 $ 0.05 $ 0.18      
Dividends, cash $ 787,000 $ 686,000 $ 576,000 $ 2,049,000      
Stock repurchase program, amount authorized           $ 70,000,000.0 $ 15,000,000.0
Treasury stock, shares acquired (in shares)       903,031 268,706    
Treasury stock, value, acquired, cost method       $ 23,700,000 $ 10,000,000.0    
Stock repurchase program, amounts available for future purchases       $ 32,000,000.0      
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details)
₩ in Millions
1 Months Ended
Jan. 31, 2016
complaint
Sep. 30, 2016
USD ($)
Sep. 30, 2016
KRW (₩)
Securities Class Action      
Loss Contingencies [Line Items]      
Number of complaints 2    
Korean Business Segment | Other Noncurrent Assets      
Loss Contingencies [Line Items]      
Distributor claims reserve   $ 203,000 ₩ 223
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
RELATED PARTY TRANSACTIONS - NARRATIVE (Detail) - Broady Health Sciences - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 29, 2015
Feb. 28, 2013
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Soothe            
Related Party Transaction [Line Items]            
Royalty rate 2.50%          
Royalty expense     $ 700 $ 1,300 $ 2,700 $ 5,200
Number of days for termination notice 120 days          
ReStore            
Related Party Transaction [Line Items]            
Royalty rate   2.50%        
Royalty expense     $ 106,000 $ 154,000 $ 386,000 $ 410,000
Number of days for termination notice   120 days        
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUBSEQUENT EVENT - NARRATIVE (Details) - $ / shares
3 Months Ended 9 Months Ended
Oct. 23, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Subsequent Event [Line Items]          
Common stock, cash dividends declared (in dollars per share)   $ 0.07 $ 0.04 $ 0.18 $ 0.09
Subsequent Event          
Subsequent Event [Line Items]          
Common stock, cash dividends declared (in dollars per share) $ 0.08        
CommonStockSpecialDividendsPerShareDeclared $ 0.35        
EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 42 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 60 162 1 false 20 0 false 7 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1002000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 1003501 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnauditedParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Statements 6 false false R7.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 7 false false R8.htm 2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION Sheet http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation NATURE OF OPERATIONS AND BASIS OF PRESENTATION Notes 8 false false R9.htm 2107100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2108100 - Disclosure - STOCK-BASED COMPMENSATION Sheet http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensation STOCK-BASED COMPMENSATION Notes 10 false false R11.htm 2109100 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 11 false false R12.htm 2110100 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 2111100 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 2112100 - Disclosure - SUBSEQUENT EVENT Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEvent SUBSEQUENT EVENT Notes 14 false false R15.htm 2207201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 2307302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 2308301 - Disclosure - STOCK-BASED COMPMENSATION (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationTables STOCK-BASED COMPMENSATION (Tables) Tables http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensation 17 false false R18.htm 2309301 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.naturalhealthtrendscorp.com/role/StockholdersEquity 18 false false R19.htm 2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NARRATIVE (Details) Details 19 false false R20.htm 2407404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CASH AND CASH EQUIVALENTS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CASH AND CASH EQUIVALENTS (Details) Details 20 false false R21.htm 2407405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - OTHER ACCRUED EXPENSES (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - OTHER ACCRUED EXPENSES (Details) Details 21 false false R22.htm 2407406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - AVAILABLE-FOR-SALE INVESTMENTS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - AVAILABLE-FOR-SALE INVESTMENTS (Details) Details 22 false false R23.htm 2407407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CHANGES IN ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CHANGES IN ACCUMULATED OTHER COMPREHENSIVE LOSS (Details) Details 23 false false R24.htm 2407408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - BASIC AND DILUTED EARNINGS PER SHARE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - BASIC AND DILUTED EARNINGS PER SHARE (Details) Details 24 false false R25.htm 2408402 - Disclosure - STOCK-BASED COMPMENSATION - NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails STOCK-BASED COMPMENSATION - NARRATIVE (Details) Details 25 false false R26.htm 2408403 - Disclosure - STOCK-BASED COMPMENSATION - RESTRICTED STOCK ACTIVITY (Details) Sheet http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails STOCK-BASED COMPMENSATION - RESTRICTED STOCK ACTIVITY (Details) Details 26 false false R27.htm 2409402 - Disclosure - STOCKHOLDERS' EQUITY - NARRATIVE (Detail) Sheet http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetail STOCKHOLDERS' EQUITY - NARRATIVE (Detail) Details 27 false false R28.htm 2410401 - Disclosure - COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details) Details 28 false false R29.htm 2411401 - Disclosure - RELATED PARTY TRANSACTIONS - NARRATIVE (Detail) Sheet http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail RELATED PARTY TRANSACTIONS - NARRATIVE (Detail) Details 29 false false R30.htm 2412401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details) Sheet http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails SUBSEQUENT EVENT - NARRATIVE (Details) Details 30 false false All Reports Book All Reports nhtc20161025_10q.htm nhtc-20160930.xsd nhtc-20160930_cal.xml nhtc-20160930_def.xml nhtc-20160930_lab.xml nhtc-20160930_pre.xml true true JSON 47 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nhtc20161025_10q.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 60, "dts": { "calculationLink": { "local": [ "nhtc-20160930_cal.xml" ] }, "definitionLink": { "local": [ "nhtc-20160930_def.xml" ] }, "inline": { "local": [ "nhtc20161025_10q.htm" ] }, "labelLink": { "local": [ "nhtc-20160930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-doc-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml" ] }, "presentationLink": { "local": [ "nhtc-20160930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-ref-2016-01-31.xml", "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml" ] }, "schema": { "local": [ "nhtc-20160930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-parts-codification-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd", "http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd", "http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd", "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd", "http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" ] } }, "elementCount": 253, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2016-01-31": 22, "http://xbrl.sec.gov/dei/2014-01-31": 7, "total": 29 }, "keyCustom": 7, "keyStandard": 155, "memberCustom": 9, "memberStandard": 11, "nsprefix": "nhtc", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Document And Entity Information", "role": "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - STOCK-BASED COMPMENSATION", "role": "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensation", "shortName": "STOCK-BASED COMPMENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - SUBSEQUENT EVENT", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent", "shortName": "SUBSEQUENT EVENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2207201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307302 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - STOCK-BASED COMPMENSATION (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationTables", "shortName": "STOCK-BASED COMPMENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DividendsDeclaredTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q1QTD", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q3", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2016Q3", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "span", "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CASH AND CASH EQUIVALENTS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CASH AND CASH EQUIVALENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q3_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "span", "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - OTHER ACCRUED EXPENSES (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - OTHER ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q3", "decimals": "-3", "lang": null, "name": "nhtc:AccruedSalesReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "span", "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407406 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - AVAILABLE-FOR-SALE INVESTMENTS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - AVAILABLE-FOR-SALE INVESTMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q3", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FI2015Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407407 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CHANGES IN ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CHANGES IN ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407408 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - BASIC AND DILUTED EARNINGS PER SHARE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - BASIC AND DILUTED EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": "0", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - STOCK-BASED COMPMENSATION - NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "shortName": "STOCK-BASED COMPMENSATION - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q1QTD", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - STOCK-BASED COMPMENSATION - RESTRICTED STOCK ACTIVITY (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails", "shortName": "STOCK-BASED COMPMENSATION - RESTRICTED STOCK ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2015Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "D2016Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - STOCKHOLDERS' EQUITY - NARRATIVE (Detail)", "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetail", "shortName": "STOCKHOLDERS' EQUITY - NARRATIVE (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "ix:continuation", "div", "ix:continuation", "body", "html" ], "contextRef": "D2016Q3", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeAxis_nhtc_KoreanBusinessSegmentMember", "decimals": "0", "first": true, "lang": null, "name": "nhtc:DistributorClaimsReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410401 - Disclosure - COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FI2016Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeAxis_nhtc_KoreanBusinessSegmentMember", "decimals": "0", "first": true, "lang": null, "name": "nhtc:DistributorClaimsReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411401 - Disclosure - RELATED PARTY TRANSACTIONS - NARRATIVE (Detail)", "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail", "shortName": "RELATED PARTY TRANSACTIONS - NARRATIVE (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember", "decimals": "INF", "first": true, "lang": null, "name": "nhtc:RoyaltyRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q3QTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details)", "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails", "shortName": "SUBSEQUENT EVENT - NARRATIVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "ix:continuation", "div", "body", "html" ], "contextRef": "D2016Q4_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SalesRevenueGoodsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "contextRef": "FD2016Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnauditedParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q3QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q3QTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION", "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation", "shortName": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "contextRef": "FD2016Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 20, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityFilerCategory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2014-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "nhtc_AccruedSalesReturns": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Sales Returns", "label": "Accrued Sales Returns", "terseLabel": "Sales returns" } } }, "localname": "AccruedSalesReturns", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_AccruedWarehousingAndInventoryRelatedExpense": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Warehousing And Inventory Related Expense", "label": "Accrued Warehousing And Inventory Related Expense", "terseLabel": "Warehousing, inventory-related and other" } } }, "localname": "AccruedWarehousingAndInventoryRelatedExpense", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_BankDepositInAnticipationOfSubmittingDirectSellingLicenseApplicationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents a bank deposit account in anticipation of submitting a direct selling license application.", "label": "Bank Deposit in Anticipation of Submitting Direct Selling License Application [Member]", "terseLabel": "Bank Deposit in Anticipation of Submitting Direct Selling License Application" } } }, "localname": "BankDepositInAnticipationOfSubmittingDirectSellingLicenseApplicationMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_BroadyHealthSciencesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Broady Health Sciences.", "label": "Broady Health Sciences [Member]", "terseLabel": "Broady Health Sciences" } } }, "localname": "BroadyHealthSciencesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "nhtc_CommonStockSpecialDividendsPerShareDeclared": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Special dividends declared during the period for each share of common stock outstanding.", "label": "CommonStockSpecialDividendsPerShareDeclared", "terseLabel": "CommonStockSpecialDividendsPerShareDeclared" } } }, "localname": "CommonStockSpecialDividendsPerShareDeclared", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "perShareItemType" }, "nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents cumulative translation adjustment realized in net income.", "label": "Cumulative Translation Adjustment Realized In Net Income", "negatedTerseLabel": "Cumulative translation adjustment realized in net income" } } }, "localname": "CumulativeTranslationAdjustmentRealizedInNetIncome", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "nhtc_DistributorClaimsReserve": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the funds which can be utilized to fund any outstanding distributor claims for product returns.", "label": "Distributor Claims Reserve", "terseLabel": "Distributor claims reserve" } } }, "localname": "DistributorClaimsReserve", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "nhtc_DocumentAndEntityInformation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Document And Entity Information" } } }, "localname": "DocumentAndEntityInformation", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "xbrltype": "stringItemType" }, "nhtc_EquityIncentive2016PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equity Incentive 2016 Plan", "label": "Equity Incentive 2016 Plan [Member]", "terseLabel": "Equity Incentive Plan 2016" } } }, "localname": "EquityIncentive2016PlanMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "nhtc_FinancialInstitutionInstrumentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information pertaining to financial institution instruments.", "label": "Financial Institution Instruments [Member]", "terseLabel": "Financial Institution Instruments" } } }, "localname": "FinancialInstitutionInstrumentsMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_KoreanBusinessSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Korean Business Segment.", "label": "Korean Business Segment [Member]", "terseLabel": "Korean Business Segment" } } }, "localname": "KoreanBusinessSegmentMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_MunicipalBondsAndNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds and Notes [Member]", "terseLabel": "Municipal Bonds and Notes" } } }, "localname": "MunicipalBondsAndNotesMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "nhtc_NumberOfDaysTerminationNotice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents number of days termination notice.", "label": "Number Of Days Termination Notice", "terseLabel": "Number of days for termination notice" } } }, "localname": "NumberOfDaysTerminationNotice", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "durationItemType" }, "nhtc_ReStoreMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents a product called ReStore\u2122.", "label": "ReStore [Member]", "terseLabel": "ReStore" } } }, "localname": "ReStoreMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "nhtc_RoyaltyRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the royalty rate.", "label": "Royalty Rate", "terseLabel": "Royalty rate" } } }, "localname": "RoyaltyRate", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "percentItemType" }, "nhtc_SecuritiesClassActionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Securities Class Action [Member]", "label": "Securities Class Action [Member]", "terseLabel": "Securities Class Action" } } }, "localname": "SecuritiesClassActionMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "nhtc_SootheMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents Soothe.", "label": "Soothe [Member]", "terseLabel": "Soothe" } } }, "localname": "SootheMember", "nsuri": "http://www.naturalhealthtrendscorp.com/20160930", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AOCIAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "AOCI Attributable to Parent [Abstract]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r37", "r43" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r34", "r239", "r251" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued commissions" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r62", "r66", "r208" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from the appreciation (depreciation) in value of securities attributable to the parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r64", "r65", "r66" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r63", "r66", "r208" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r59", "r66", "r208" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r38" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r175", "r184", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Share-based compensation expense", "verboseLabel": "Stock-based compensation expense included in selling, general, and administrative expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnauditedParenthetical", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r0", "r6", "r8", "r114" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r238", "r250" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r24", "r25", "r57" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [ "r126", "r127", "r130" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available-for-sale Securities", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax", "terseLabel": "Gross Unrealized Gains (Losses)" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [ "r48" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Adjusted Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [ "r128", "r129", "r131", "r132", "r133", "r245", "r246" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Available-for-sale Securities" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r176", "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by award type pertaining to equity-based compensation.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r211", "r212" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r3", "r22", "r44", "r90" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period", "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [ "r84", "r217" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r2", "r3", "r31", "r91", "r97", "r123" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r31", "r91", "r97", "r123", "r237" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r3", "r31" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r2", "r31" ], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants, number of securities called by warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r52", "r142", "r241", "r255" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r52", "r141", "r146", "r152", "r216" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends paid (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common stock, cash dividends declared (in dollars per share)", "verboseLabel": "Common (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r36" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at September 30, 2016 and December 31, 2015" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r5", "r13", "r14", "r69" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss, net of tax:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r97", "r206", "r209", "r210" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r92", "r93", "r94" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "terseLabel": "Conversion of Stock, Amount Converted" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsSold": { "auth_ref": [ "r76" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs related to goods produced and sold during the reporting period.", "label": "Cost of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r51", "r104", "r155", "r158", "r159", "r160", "r224", "r225", "r226", "r248" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.", "label": "Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent", "verboseLabel": "Long-term incentive" } } }, "localname": "DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r28", "r167", "r168", "r169", "r170", "r171", "r172" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.", "label": "Deferred Revenue, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesCurrent": { "auth_ref": [ "r193", "r194", "r195", "r200", "r201" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as current.", "label": "Deferred Tax Liabilities, Net, Current", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredTaxLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r88", "r139" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation and amortization" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r88" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r166", "r176", "r186", "r187", "r188", "r190" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "STOCK-BASED COMPMENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dividends [Abstract]", "terseLabel": "Cash dividends declared per share:" } } }, "localname": "DividendsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_DividendsCash": { "auth_ref": [ "r161", "r247" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.", "label": "Dividends, Cash", "terseLabel": "Dividends, cash" } } }, "localname": "DividendsCash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsDeclaredTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.", "label": "Dividends Declared [Table Text Block]", "terseLabel": "Schedule of cash dividend activity" } } }, "localname": "DividendsDeclaredTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r73", "r110", "r115", "r117", "r244", "r257" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Net income allocated to common stockholders (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted-average number of common shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r73", "r110", "r244", "r257" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Net income allocated to common stockholders plus assumed conversions (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r97", "r114", "r115", "r116" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Income Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r217" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee-related" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unrecognized cost of unvested share-based compensation awards.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Share-based compensation expense not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Recognition period for compensation costs not yet recognized (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r184" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.", "label": "Employee Service Share-based Compensation, Tax Benefit from Compensation Expense", "terseLabel": "Tax benefit attributable to stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r97", "r214", "r215" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r136", "r137", "r138" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r75" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeAxis": { "auth_ref": [ "r249", "r259" ], "lang": { "en-US": { "role": { "documentation": "Information by guarantee for guaranteed benefit obligations in traditional and nontraditional long-duration contracts with policy and contract holders.", "label": "Guaranteed Insurance Contract, Type of Guarantee [Axis]", "terseLabel": "Guaranteed Insurance Contract, Type of Guarantee [Axis]" } } }, "localname": "GuaranteedInsuranceContractTypeOfGuaranteeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GuaranteedInsuranceContractTypeOfGuaranteeDomain": { "auth_ref": [ "r249", "r259" ], "lang": { "en-US": { "role": { "documentation": "Guarantee for guaranteed benefit obligations in traditional and nontraditional long-duration contracts with policy and contract holders.", "label": "Guaranteed Insurance Contract, Type of Guarantee [Domain]", "terseLabel": "Guaranteed Insurance Contract, Type of Guarantee [Domain]" } } }, "localname": "GuaranteedInsuranceContractTypeOfGuaranteeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r71", "r236", "r242", "r258" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r10", "r105", "r202" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r97", "r191", "r192", "r198", "r199", "r203", "r263" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r196", "r197" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "terseLabel": "Repatriation of foreign earnings" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued commissions" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement, or (c) a combination of (a) and (b).", "label": "Increase (Decrease) in Customer Advances and Deposits", "terseLabel": "Amounts held in eWallets" } } }, "localname": "IncreaseDecreaseInCustomerAdvancesAndDeposits", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.", "label": "Increase (Decrease) in Deferred Compensation", "terseLabel": "Long-term incentive" } } }, "localname": "IncreaseDecreaseInDeferredCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInRestrictedCash": { "auth_ref": [ "r11", "r80", "r82" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.", "label": "Increase (Decrease) in Restricted Cash", "negatedTerseLabel": "Increase in restricted cash" } } }, "localname": "IncreaseDecreaseInRestrictedCash", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r1", "r18", "r19", "r111", "r113" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Warrants to purchase common stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r112", "r115" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Non-vested restricted stock (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r23", "r55", "r135" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r213", "r260", "r261", "r262" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r213", "r260", "r261", "r262" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r47" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r42", "r240", "r253" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r142", "r143", "r144", "r146", "r147", "r148", "r149", "r150", "r151" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Number of complaints" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r84", "r86" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r84", "r86" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r84", "r85", "r89" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r13", "r14", "r72", "r89", "r115", "r243", "r256" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r108" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net income available to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r108", "r109" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net income allocated to common stockholders plus assumed conversions" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued and Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r27", "r29", "r30", "r49" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "totalLabel": "Total other accrued expenses", "verboseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesOtherAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r60", "r64", "r218", "r219", "r222", "r223" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r58", "r220" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "totalLabel": "Net change in foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "auth_ref": [ "r64", "r67", "r68", "r221" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "negatedTerseLabel": "Release of cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r204", "r205", "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r61", "r64" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Unrealized (losses) gains on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDeferredCreditsCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unearned revenue or income classified as other, expected to be taken into income within one year or the normal operating cycle, if longer.", "label": "Other Deferred Credits, Current", "verboseLabel": "Amounts held in eWallets" } } }, "localname": "OtherDeferredCreditsCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r26", "r27", "r49" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "verboseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r9", "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r9", "r83" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments of Dividends", "negatedLabel": "Dividends paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r11", "r81" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment, net" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r176", "r186" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name pertaining to equity-based compensation arrangements.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the equity-based compensation arrangement plan.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r35" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r35" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductOrServiceAxis": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "Information by products and services or groups of similar products and services.", "label": "Products and Services [Axis]", "terseLabel": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ProductsAndServicesDomain": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Products and Services [Domain]", "terseLabel": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r32", "r33", "r140", "r254" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r66", "r70" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "terseLabel": "Amounts reclassified out of accumulated other comprehensive loss" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r12", "r16", "r17", "r227", "r228", "r229" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r230", "r231", "r232", "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r103", "r230", "r231", "r232", "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": { "auth_ref": [ "r3", "r44" ], "lang": { "en-US": { "role": { "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.", "label": "Restricted Cash and Cash Equivalents [Axis]", "terseLabel": "Restricted Cash and Cash Equivalents [Axis]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r39", "r161", "r252" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r95", "r97", "r98", "r173" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r77" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesCommissionsAndFees": { "auth_ref": [ "r78" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).", "label": "Sales Commissions and Fees", "terseLabel": "Commissions expense" } } }, "localname": "SalesCommissionsAndFees", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueGoodsNet": { "auth_ref": [ "r74" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.", "label": "Sales Revenue, Goods, Net", "terseLabel": "Net sales" } } }, "localname": "SalesRevenueGoodsNet", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r103", "r230", "r231", "r232", "r233", "r234" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r176", "r186" ], "lang": { "en-US": { "role": { "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentGeographicalDomain": { "auth_ref": [ "r21", "r122", "r264" ], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r78", "r134" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses (including stock-based compensation expense of $10 and $21 during the three months ended September 30, 2016 and 2015, respectively, and $94 and $56 during the nine months ended September 30, 2016 and 2015, respectively)" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additional share-based compensation cost recognized as a result of an occurrence of an event that accelerates its recognition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost", "terseLabel": "Additional stock-based compensation expense" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, ending balance (in shares)", "periodStartLabel": "Nonvested, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, ending balance (in dollars per share)", "periodStartLabel": "Nonvested, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r174", "r179" ], "lang": { "en-US": { "role": { "documentation": "Equity-based compensation award.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r95", "r96", "r97", "r99", "r100" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r54", "r154" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockBasedCompmensationNarrativeDetails", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementGeographicalAxis": { "auth_ref": [ "r21", "r122", "r264" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r92", "r93", "r94" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "terseLabel": "Issuance of treasury stock" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Stock repurchase program, amount authorized" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, amounts available for future purchases" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r36", "r40", "r41", "r124" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesChangesInAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r15", "r36", "r40", "r41", "r101", "r102", "r125", "r153", "r154", "r155", "r156", "r157", "r158", "r161", "r162", "r164" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENT" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r53", "r163" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r36", "r154", "r161" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury stock, shares acquired (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r53", "r163", "r165" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost; 1,692,218 and 840,202 shares at September 30, 2016 and December 31, 2015, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r154", "r161", "r163" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "terseLabel": "Treasury stock, value, acquired, cost method" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r118", "r119", "r120" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r109", "r113" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Net income allocated to common stockholders plus assumed conversions (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r20", "r107", "r113" ], "calculation": { "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Net income allocated to common stockholders (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2016-01-31", "presentation": [ "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited", "http://www.naturalhealthtrendscorp.com/role/SummaryOfSignificantAccountingPoliciesBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Glossary": "Antidilution", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6505113" }, "r1": { "Glossary": "Call Option", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506649" }, "r10": { "Glossary": "Income Tax Expense (or Benefit)", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6515339" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18861-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256" }, "r11": { "Glossary": "Investing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6516133" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1757-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1500-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6061-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6132-108592" }, "r12": { "Glossary": "Management", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6517382" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=64851502&loc=d3e6143-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "305", "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563" }, "r13": { "Glossary": "Net Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831255" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r14": { "Glossary": "Other Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831270" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349" }, "r15": { "Glossary": "Preferred Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521494" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644" }, "r16": { "Glossary": "Principal Owners", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6521851" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=68057994&loc=d3e25284-112666" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 13.A.4(a).Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q1(c))", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r17": { "Glossary": "Related Parties", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=16382449" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(b).Q2)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3(c).Q3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.A.3)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 13.B.Q1)", "Topic": "605", "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r18": { "Glossary": "Treasury Stock Method", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6527216" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809" }, "r19": { "Glossary": "Warrant", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528364" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=65895303&loc=d3e17540-113929" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319" }, "r2": { "Glossary": "Cash", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6506951" }, "r20": { "Glossary": "Weighted-Average Number of Common Shares Outstanding", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6528421" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32621-109319" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32632-109319" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569643-111683" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-04.(c) Schedule III)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32022-110900" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32157-110900" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400" }, "r227": { "Glossary": "Affiliate", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6504562" }, "r228": { "Glossary": "Control", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6508935" }, "r229": { "Glossary": "Immediate Family", "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6515043" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6588021&loc=d3e7104-158389" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "225", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28)", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r265": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12b", "Subsection": "1" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765" }, "r3": { "Glossary": "Cash Equivalents", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6507016" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Glossary": "Common Stock", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508022" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Glossary": "Comprehensive Income", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=51831223" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r6": { "Glossary": "Contingent Stock Agreement", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6508534" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e),(f),(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580" }, "r7": { "Glossary": "Current Liabilities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6509677" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=66004921&loc=d3e1436-108581" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "225", "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688" }, "r8": { "Glossary": "Diluted Earnings Per Share", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6510752" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3179-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585" }, "r9": { "Glossary": "Financing Activities", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "http://asc.fasb.org/extlink&oid=6513228" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18726-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18743-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18823-107790" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18854-107790" } }, "version": "2.0" } ZIP 48 0000912061-16-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000912061-16-000043-xbrl.zip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�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end